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ABSTRACT
Statistical Modeling for Cellular Heterogeneity Problems in Cancer Research:
Deconvolution, Gaussian Graphical Models and Logistic Regression
by
Zeya Wang
Tumor tissue samples comprise a mixture of cancerous and surrounding normal
cells. Investigating cellular heterogeneity in tumors is crucial to genomic analyses
associated with cancer prognosis and treatment decisions, where the contamination
of non-cancerous cells may substantially a↵ect gene expression profiling in clinically
derived malignant tumor samples. For this purpose, we first computationally purify
tumor profiles, and then develop new statistical modeling techniques to incorporate
tumor purity estimates for genetic correlation and prediction of clinical outcome in
cancer research. In this thesis, we propose novel approaches to analyzing and mod-
eling cellular heterogeneity problems using genomic data from three perspectives.
First, we develop a computation tool, DeMixT, which applies a deconvolution al-
gorithm to explicitly account for at most three cellular components associated with
cancer. Compared with the experimental approach to isolate single cells, in silico
dissection of tumor samples is faster and cheaper, but computational tools previously
developed have limited ability to estimate cellular proportions and tumor-specific
expression profiles, when neither is given with prior information. Our model al-
lows inclusion of the infiltrating immune cells as a component as well as the tumor
cells and stromal cells. We assume a linear mixture of gene expression profiles for
each component satisfying a log2-normal distribution and propose an iterated con-
ditional modes algorithm to estimate parameters. We also involve a novel two-stage
estimation procedure for the three-component deconvolution. Our method is com-
putationally feasible and yields accurate estimates through simulations and real data
analyses. The estimated cellular proportions and purified expression profiles can pro-
vide deeper insight for cancer biomarker studies. Second, we propose a novel edge
regression model for undirected graphs, which incorporates subject-level covariates
to estimate the conditional dependencies. Current work for constructing graphical
models for multivariate data does not take into account the subject specific informa-
tion, which can bias the conditional independence structure in heterogeneous data.
Especially for tumor samples with inherent contamination from normal cells, ignor-
ing the cellular heterogeneity and modeling the population-level genomic graphs may
inhibit the discovery of the true tumor graph, which would be attenuated towards
the normal graph. Our model allows undirected networks to vary with the exogenous
covariates and is able to borrow strength from di↵erent related graphs for estimating
more robust covariate-specific graphs. Bayesian shrinkage algorithms are presented
to e ciently estimate and induce sparsity for generating subject-level graphs. We
demonstrate the good performance of our method through simulation studies and
apply our method to cytokine measurements from blood plasma samples from hepa-
tocellular carcinoma (HCC) patients and normal controls. Third, we build a model
with respect to logistic regression that includes tumor purity as a scaling factor to
improve model robustness for the purpose of both estimation and prediction. Penal-
ized logistic regression is used to identify variables (genes) and predict clinical status
with binary outcomes that are associated with cancers in high-dimensional genomic
data. We aim to reduce the uncertainty introduced by cellular heterogeneity through
incorporating the measure of tumor purity to quantify the power of data for each
sample. We provide strategies of choosing scaling parameters. Our model is finally
shown to work well through a set of simulation studies. We believe that the statis-
tical modeling, technical pipelines and computational results included in our work
will serve as a first guide for the development of statistical methods accounting for
cellular heterogeneity in cancer research.
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1Chapter 1
Introduction
Cellular heterogeneity has been documented as a crucial factor in cancer prognosis
or treatment for many years. In genomic analyses, expression profiles observed from
tumor samples can be contaminated and even dominated by non-cancer cells (nor-
mal cells). In this thesis, we propose three topics by applying di↵erent statistical
modeling techniques from di↵erent perspectives for cellular heterogeneity problems
in cancer research. The first topic involves in silico dissection of tumor samples using
expression data. The second topic focuses on more general covariate-dependent undi-
rected graphical models while accounting for biological heterogeneity in construction
of regulatory networks. The third topic deals with penalized logistic regression by in-
troducing heterogeneity to classification of binary outcomes. This chapter introduces
our motivation and contributions as well as the background and problem. Section
1.1 gives a description of the well-defined problems for cellular heterogeneity. Sec-
tion 1.2 explains our scientific motivations for this problem. Section 1.3 provides an
outline of the dissertation and an overview of our methods. Section 1.4 describes our
contributions.
1.1 Cellular Heterogeneity of Tumors
Tumor is not just one whole blob (Fig. 1.1). Solid tumors are heterogeneous from a
morphological prospective. Tumors are neoplasm that grow within an intricate en-
2vironment composed of di↵erent types of cells (Marusyk et al., 2012). Cancer cells
“huddle” with a highly diverse cell populations, including epithelial cells, mesenchy-
mal cells, endovascular cells, cytokines and chemokines, and infiltrating immune cells
(Marusyk et al., 2012). This very complex tissue architecture of tumors defines the
cellular heterogeneity problem (Gay et al., 2016; Sun and Yu, 2015; Marjanovic et al.,
2013; Meacham and Morrison, 2013; Marusyk et al., 2012; Xu et al., 2014). Ac-
tually, each population is also heterogeneous as a mixture of di↵erent cells. Those
non-cancerous cells are from surrounding healthy tissues, which are interacted with
cancer stem cells during the tumor growth and disease progression, including local-
ization, growth, invasion, extravasation, therapy resistance and metastasis (Pages
et al., 2009). Not only the cancer cells, but also those cells involved will determine
the progression of cancer, and cause molecular di↵erences in tumors. Those di↵er-
ences a↵ect clinical diagnostics and therapeutic response, which can cause dramatical
variations even for cancer patients with very similar clinical characteristics. Tumor
purity, which is the percentage of cancerous cells and also defines the degree about
how tumor genome sequence di↵er from the normal’s after genetic mutation, can vary
widely among samples, even with a high cancerous content for the same cancer type
(Su et al., 2012; Quon et al., 2013).
Gene/protein expression profiling are measurements of mRNA/active protein level to
provide a high-resolution picture of molecular functions (Liotta and Petricoin, 2000).
They determine the pattern of gene expression, and can be used to detect the under-
lying transcriptional activity and reveal its aberrant behaviors (Liotta and Petricoin,
2000; Quon and Morris, 2009). A lot of statistical methods based on gene/protein
expression profiles are developed for genomic analyses in cancer research, but a ma-
jority of current analysis methods treat cancer as homogeneous and do not account for
3this aspect of cellular heterogeneity, which introduces variability/noises into expres-
sion profiles (Aran et al., 2015). This variability is hard to be removed by available
analytic methods and may confuse the detection of gene signatures associated with
cancer prognosis. Furthermore, those confounding transcriptional signals brought by
non-cancerous cells will reduce the e↵ective sample size and thus the statistical power
for genomic studies in cancer (Quon et al., 2013). It has been widely believed that
the utility of profiles with common analytical techniques is limited by cellular hetero-
geneity in tumors (de Ridder et al., 2005).
(a) Tumor comprises cancerous tissues
and healthy tissues. Multiple samples ex-
tracted from the same tumor have di↵er-
ent proportions of constituent tissues and
exhibit di↵erent expression profiles. (Fig-
ure source: (Quon and Morris, 2009))
(b) Tumor core is interwoven with im-
mune contexture (the invasive margin,
tertiary lymphoid structures, et.al.) and
tumor microenvironment (stroma, et.al).
(Figure source: (Fridman et al., 2012))
Figure 1.1 : Demonstration for cellular heterogeneity in tumors.
41.2 Scientific Motivation
Our works, in this thesis, stem from the fact that cancer is heterogeneous at the
cellular and molecular levels. Cellular heterogeneity problems may significantly bias
analyses based on gene expression profiles and lead to false conclusions (Farley, 2015).
Statistical modeling and methods are important tools used to find biomarkers for can-
cer prognosis and treatment. But this cellular heterogeneity problem has not been
thoroughly investigated, and thus can bring those negative e↵ects mentioned previ-
ously. As a consequence, extracting tumor purity from mixed tumor samples and
modeling compartment-specific information are required for us to seek for significant
improvements in cancer research.
We are first motivated to deconvolve the observed expression profiles of tumor samples
into those contributed by di↵erent cell sub-populations/types (Xu et al., 2014). We
believe that for a set of cell type-specific genes, expression profiles uniquely reflect the
functional characteristics of the corresponding cell types. A deconvolution (deconvo-
lution) framework is developed to decompose the expression dataset collected from
tumor samples, which are assumed as a mixture of di↵erent cell types, into expression
profiles specific to each component. This is our first step, but also the key step. Af-
ter deconvolution, we obtain the proportions of assumed cancerous component, which
correspond to the tumor purity mentioned above. We first begin with the assumption
that a solid tumor sample is a mixture of two distinct components, cancerous and
non-cancerous (e.g., normal), which has been frequently assumed in other literature
and works (Ahn et al., 2013; Wang et al., 2015). This simple assumption allows de-
convolution to be performed under a clearer context, but we need to overcome several
challenges for deconvolution technique. A more relaxed model is expected to include
more subdivided components, when we realize the immune contexture is a crucial
5factor on tumor (Fridman et al., 2012). A better deconvolution algorithm helps us to
get better estimates of tumor purity and model expressions contributed by separate
cell types more accurately.
Following the work of tumor deconvolution, we investigate how to incorporate tu-
mor purity estimates into statistical modeling for genetic correlation and prediction
of clinical outcome, which are two of the most common approaches used in cancer
research. Gaussian graphical models are usually applied, when gene regulatory net-
works are constructed to model the regulatory relationships among genes and their
products. Tumor purity may introduce nontrivial bias into the constructed networks,
when a lot of current works consider tumor samples as homogeneous following our
previous discussion. More interestingly, the variability brought by di↵erence of tumor
purity for patient samples can give rise to topological change in the regulatory net-
works, which drive the progression of cancer, at an individual level. Thus, we want to
include a “personalized” network instead of a general network for all those patients
(Ni et al., 2017). This work can be complicated because we need to maintain the
“personalized” conditional dependency structure among genes for all the individual
samples. More generally speaking, current statistical work for constructing graphical
models for multivariate data does not take into account the subject specific informa-
tion. We believe this can inhibit the discovery of the true conditional dependency
structure in the heterogeneous data. We are motivated to develop a more general
statistical framework for subject-varying graphical models. Diagnostic classification
of clinical status for patients and finding predictive genes for case-control disease is
an integral part in cancer research. Logistic regression is a standard method used
to implement binary classification and feature selection with penalized likelihood in
genomic studies. The contamination of normal cells and the measurement error of
6deconvolved expression data can mislead the prediction of clinical outcome mainly
associated with cancerous component. Therefore, we want to elicit a model to quan-
tify and introduce the uncertainty caused by tumor purity into the logistic regression
for cancer data.
1.3 Outline of the Dissertation
In this dissertation, we aim at di↵erent statistical methods for the cellular heterogene-
ity problems mainly from three prospective, including deconvolution, Gaussian graph-
ical models and logistic regression. The goal of our modeling and analysis approach
is to improve the power of conventional statistical tools in cancer research, when the
heterogeneity in data undermines their assumptions. In each di↵erent work, we first
extract the cancer specific information from the clinically derived malignant tumor
samples and integrate this subject-level information into the downstream biomarker
studies. We build and test our models on simulated data and real data, which include
microarray expression data, RNA-seq expression data and even cytokine expression
data. The focus of this dissertation is the performance of our method in each section
and biological findings we discover by applying our methods.
The first chapter of this thesis is an introductory overview of the cellular hetero-
geneity problems in cancer research and its background information. We explain the
statistical and biological significance of addressing those problems and take a review
of the challenges we are facing. We also point out contributions of our work as well
as implications for the future studies.
The following three chapters address three topics: deconvolution, Gaussian graphical
models and logistic regression, for cellular heterogeneity problem. Chapter 2 describes
7the work on the transcriptome deconvolution of mixed tumor samples with immune
infiltration. Deconvolution, which is the process of resolving the observed gene ex-
pression data into expressions contributed by di↵erent components we assume for
di↵erent cell types, is realized by finding an appropriate derivative-free optimization
procedure for a log-normal distribution based model. We begin to model two separate
components for cancerous and non-cancerous tissues and extend to three components
in our model first to accommodate the existence of infiltrating immune cells. We
develop an R package DeMixT to incorporate all those features we build for tumor
deconvolution and make it to be implemented fast and easily. We demonstrate results
for estimating component-specific proportions and deconvolved expressions through
several computationally and biologically simulated datasets, and one real biological
data set. We also reveals several interesting biological findings after applying our
deconvolution tool.
The next two chapters investigate biomarker studies for tumor samples from the
perspective of constructing gene regulatory networks and performing diagnostic pre-
diction. Chapter 3 presents the work on the Bayesian edge regression. We introduce a
novel class of Bayesian edge selection model to allow the topology of high-dimensional
undirected graphs dependent on exogenous covariates in a flexible way. We define our
edge regression model for undirected graphs and provide some theoretical properties
of our model. We propose a joint regression model with a Bayesian inference approach
to preserve the symmetry among the partial correlations, which is ignored by all those
methods developed previously for conditional covariance selection. We validate our
model in two cases for continuous and categorical exogenous covariates by comparing
with several competitive methods. Specifically, the case for continuous covariates is
simulated corresponding to the assumed model in the tumor deconvolution problem,
8so that we can employ it directly to estimate varying structure networks for tumor
samples with di↵erent tumor purity. Finally, we illustrate the application of our edge
regression model in a liver cancer cytokine study to estimate blood plasma cytokine
networks induced by hepatocellular carcinoma and those from normal controls while
accounting for biological heterogeneity. In Chapter 4, we develop a logistic regression
model with a scaling factor function, which can be also applied in a penalized form.
For diagnostic prediction for tumor samples, we consider observations with di↵erent
tumor purity to contribute di↵erently to predicting binary outcomes associated with
tumors. Our model allows tumor purity to control the mean of the Bernoulli dis-
tribution through linking it with the scaling parameter in the sigmoid function. We
present how to realize it in the logistic regression with and without penalty term, and
finally validate our model through the simulation study.
Finally, Chapter 5 is a concluding section to summarize our work. We also point
out several aspects from our current work, which can be extended and would become
interesting development in the future for study of cellular heterogeneity problem.
1.4 Contribution
As discussed in the previous section, statistical modeling for cellular heterogeneity
should necessarily soon be built into cancer research in the clinical and laboratory.
Tumor purity cannot be a neglected factor in any genomic studies based on tumor
samples. Existing methods that primarily focus on tumor deconvolution problem still
have limited utility, and there are few statistical methods developed to consider the
intrinsic heterogeneity of tumor samples in the downstream analysis for biomarker
studies. The contributions of this dissertation are as follows. First, we propose a sta-
9tistical method to jointly estimate tumor proportions and cancerous expressions when
neither is given with prior knowledge. Our method is able to accurately deconvolve
tumor samples into two or three cell subpopulations, which accommodate infiltrating
immune cells as a single component, and allow for more variations on the referenced
normal components. Second, we develop an R-package to integrate all those features
we propose for deconvolution into standard R-based analysis pipeline. Our package
is user friendly and easy for testing and modifying. Third, we begin to talk about the
identifiability problem in deconvolution, which has been ignored in all the previous
works and provide several suggestions in our discussion. Moreover, being motivated
by how tumor purity a↵ects co-expression network, we introduce a new class of undi-
rected graphical model, Bayesian edge regression, to allow the undirected network
structure vary with additional subject-level covariates and borrow strength from dif-
ferent related graphs for estimating more robust covariate-specific graphs. We further
apply our novel edge regression model to the cellular heterogeneity problem, to infer
more robust tumor and normal graph as well as subject-level graphs, for di↵erent can-
cer samples, therefore facilitate more meaningful biological interpretation. Finally,
we incorporate tumor purity into classification of binary outcomes for genome-wide
association study to improve the prediction performance.
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Chapter 2
Cell type-specific Deconvolution of Heterogeneous
Tumor Samples using Expression Data
2.1 Abstract
Following the discussion above, it is crucial to analyze gene signatures associated with
cancer prognosis and treatment decisions by investigating their cellular heterogene-
ity. To begin with this study, we first need to deconvolve observed expression data of
tumor samples. Compared with the experimental approach of laser micro-dissection
to isolate di↵erent tissue components (Emmert-Buck et al., 1996), in silico dissection
of mixed cell samples, which is enabled through computational tools, is faster and
cheaper. Computational approaches previously developed have their limitations to
deconvolve tumor profiles. We have developed a deconvolution model, DeMixT, which
has been integrated to the R package DeMixT, that can explicitly account for at most
three components of tumor mixtures. Our method is able to address this challenging
problem when the observed signals in tumor profiles are assumed to come from a
mixture of cancerous tissues, infiltrating immune cells and tumor microenvironment
or a mixture of just cancerous and non-cancerous tissues. DeMixT is computation-
ally feasible when it is needed to compute high-dimensional integrals, and involves
a novel two-stage filtering method that yields accurate estimates of cell type-specific
proportions and compartment-specific expression profiles. Simulations and real data
analyses have demonstrated the good performance of our method. DeMixT allows
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for a further understanding of cellular heterogeneity in cancer, therefore assists the
development of novel prognostic markers and therapeutic strategies.
2.2 Introduction
Heterogeneity of malignant tumor cells adds confounding complexity to cancer treat-
ment. From carcinoma ‘in situ’, tumor interacts with its microenvironment, which are
comprised of non-cancerous stromal and immune cells, during the cancer progression
stages of localization, growth, invasion, extravasation and metastasis (Kalluri and
Zeisberg, 2006; Pages et al., 2009; Fridman et al., 2012).The evaluation of individual
component of tumor samples is complicated by tumor-stroma interaction and tumor
infiltration by lymphocytes, macrophages or mast cells. Experimental approaches,
such as laser micro-dissection and cell sorting, are limited by their economic and time
costs. The vast expression datasets, which are generated by gene expression profiling
technique, motivate the development of computational tools to deconvolve mixed tu-
mor samples on the expression levels (de Ridder et al., 2005; Shen-Orr and Gaujoux,
2013).
A majority of methods for in silico deconvolving tumor samples are developed to de-
convolve transcriptomes by using microarray expression data and HTS data (Yadav
and De, 2015). There are two challenges that lack to be solved by most available
methods for deconvolution: (i) no violation of linear additive relationship of between
tumor profiles and its constituent profiles; (ii) estimation of both cell type-specific
proportion and tumor-specific expression for individual samples at the same time
when neither is given with priori (Ahn et al., 2013). Several approaches require ref-
erence gene sets to be imported into their pipelines (Gong and Szustakowski, 2013;
Ahn et al., 2013). Some method deconvolves two samples at a time, but is not able to
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identify cancerous and non-cancerous components (Wang et al., 2015). Several meth-
ods are developed following a matched pattern design, which requires tumor samples
and reference normal samples to be derived from the same individual (Quon et al.,
2013; Ahn et al., 2013). However, the clinical routine that deconvolves tumor samples
in an unmatched pattern limits the application of those computational tools.
Most commonly available deconvolution methods assume that malignant tumor cells
consist of two distinct components, epithelium-derived tumor and surrounding stro-
mal cells. However, immune infiltration to tumor cells is a crucial factor in cancer
prognosis. Evidence from epidemiological studies suggests that chronic inflammation,
which is initiated and stimulated by immune cells, promotes tumor growth (Pages
et al., 2009). Anatomical studies of the tumor-immune cell contexture have demon-
strated that it primarily consists of a tumor core, lymphocytes and the tumor mi-
croenvironment (Pages et al., 2009; Fridman et al., 2012). Further research supports
the association of infiltrating immune cells with clinical outcome for individuals with
ovarian cancer, colorectal cancer and follicular lymphoma (Zhang et al., 2003; Dave
et al., 2004; Galon et al., 2006). Therefore, understanding the heterogeneity of tumor
cells motivates a computational method to integrate reconstruction of expression pro-
files for immune cells in addition to the cancerous cells with its microenvironment.
Other deconvolution methods for more than two compartments require knowledge of
cell-component-specific gene lists (Liebner et al., 2014; Yoshihara et al., 2013), but do
not provide joint estimates of tissue proportion and tissue-specific gene expression.
In this work, we develop a statistical approach, DeMixT, for deconvolution of gene
expression data from mixed tumor samples that is able to account for at most three
components. It di↵ers from previous methods in its ability to estimate cell-type-
specific proportions and then the full expression matrices for all assumed mixing
13
components (Fig. 2.1). We take advantage of normality of log2-transformed expres-
sion data as well as the linear addition of raw expression data from constituent tissues
for tumor profiles (Ahn et al., 2013; Lo¨nnstedt and Speed, 2002). We integrate our
method into DeMixR pakcage as a new feature that can be applied to deconvolve tu-
mor profiles into components from cancerous, stromal and immune cells. It is known
that the immune component is heterogeneous, as its own composition varies in terms
of immune cell types. However, it was reported that the level of heterogeneity within
this component may be similar and consistent for its relative proportions of immune
cell types (Gentles et al., 2015). Therefore, that is the reason we may be able to
model expressions of tumor-infiltrating immune cells as a single component made up
of a stable mixture of immune cell types. DeMixT finds a good local optimum by
employing the method of iterated conditional modes that cyclically maximizes the
probability of each variable conditionally on the rest, for which we have observed
rapid convergence. DeMixT also utilizes a novel two-stage method to filter out re-
liable expression measurements to remove biological noise and improve estimation
performance. In the next, we demonstrate the performance of DeMixT through sim-
ulation studies and real data analyses.
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Figure 2.1 : Three-component deconvolution to output tissue-specific proportion,
and isolated expression matrices of tumor, stromal and immune cells. Heat map of
expression levels uncovers the di↵erence in gene expression patterns between original
tumor samples, deconvolved tumor components, stromal components and immune
components
2.3 Methods
2.3.1 Deconvolution model
Let Yig be the observed expression levels of the raw measured data from clinically
derived malignant tumor samples for gene g, g = 1, · · · , G and sample i, i = 1, · · · , S.
G denotes the total number of features (e.g., probes or genes) and S denotes the
number of samples. The observed expression levels for solid tumors can be modeled
as a linear mixture of raw expression levels from of its constituents (Ahn et al., 2013).
The immune composition in bulk tumors is also heterogeneous, which complicates the
model if all the specific tumor infiltrating immune cell subsets need to be included.
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However, it was recently reported that given a cancer type, even when multiple sub-
sets exist, the relative composition of leukocyte cells is consistent across di↵erent
samples (Gentles et al., 2015). Therefore, for solid tumors of some specific cancer
type, heterogeneous immune composition, considered as a consistent combination of
di↵erent subsets, can be assumed as one mixing component in our model:
Yig = ⇡1,iN1,ig + ⇡2,iN2,ig + (1  ⇡1,i   ⇡2,i)Tig (2.1)
Let N1,ig, N2,ig and Tig be the unobserved expression levels from di↵erent components.
For simplicity, we call the first two components N1-component and N2-component,
the distribution parameters of which can be estimated from reference profiles for
each tissues type. Those two components can be reduced to one, generating a two-
component deconvolution model that has often been assumed for the cancerous and
non-cancerous tissue. We define the last component as T-component, which refers to
the unknown component that is not given with any previous information. Our model
is di↵erent from previous methods by allowing one component to be unknown so not
requiring reference profiles from all the constituents. A set of unmatched observa-
tions for N1,ig, N2,ig is provided for deconvolution. The source of these unmatched
observations is from other patients or historical data. ⇡1,i denotes the proportion of
stromal cells (N1-component) and ⇡2,i denotes the proportion of immune cells (N2-
component). Thus, 1   ⇡1,i   ⇡2,i is the proportion of tumor (T-component) cells.
We assume that the mixing proportions of one specific sample are the same across all
genes.
Following the convention that log2-transformed microarray gene expression data fol-
low a normal distribution, we assume that the raw measures N1,ig ⇠ LN(µN1g,  2N1g),
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N2,ig ⇠ LN(µN2g,  2N2g) and Tig ⇠ LN(µTg,  2Tg), where LN denotes a log2-normal dis-
tribution and  2N1g, 
2
N2g, 
2
Tg reflect the variations under log2-transformed data (Ahn
et al., 2013; Lo¨nnstedt and Speed, 2002).
This mixed model can be expressed as the convolution of the density function for
three log2-normal distributions. Because there is no closed form of this convolution,
numerical integration was used to evaluate the likelihood function
L =
SY
i=1
GY
g=1
f(yig
  µTg , µN1g , µN2g , µT N1g ,  N2g ,  Tg , ⇡1,i, ⇡2,i)
/
SY
i=1
GY
g=1
{
Z y
0
1
n02,ig N2g
exp[ {log 2(n
0
2,ig)  µN2g   log 2(⇡2,i)}2
2 2N2g
]
⇥
Z y n02
0
1
n01,ig N1g
exp[ {log 2(n
0
1,ig)  µN1g   log 2(⇡1,i)}2
2 2N1g
]
1
(yig   n01,ig) Tg
⇥ exp[ {log 2(yig   n
0
1,ig   n02,ig)  µTg   log 2(1  ⇡1,i   ⇡2,i)}2
2 2Tg
]dn01,igdn02,ig}
(2.2)
, where n01,ig = ⇡1,in1,ig and n
0
2,ig = ⇡2,in2,ig
2.3.2 Inference
Two-step approach
DeMixT estimates all parameters (including cellular proportions) in equation 2.2 and
reconstitutes the expression profiles in two steps.
1. Obtain a set of parameters {⇡1,i, ⇡2,i}Si=1, {µT ,  T}Gg=1 to maximize the complete
likelihood function after inferring {µN1,g ,  N1,g , µN2,g ,  N2,g}Gg=1 from unmatched
samples for N1 and N2-component tissues.
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2. Reconstitute the expression profiles by searching each pair of {n1,ig, n2,ig} that
maximize the joint density of N1,ig, N2,ig and Tig
argmax
n1,ig ,n2,ig
 (
yig   ⇡ˆ1,in1,ig   ⇡ˆ2,in2,ig
1  ⇡ˆ1,i   ⇡ˆ2,i
  µˆTg ,  ˆTg ) (n1,ig   µˆN1g ,  ˆN1g ) (n2,ig   µˆN2g ,  ˆN2g )
(2.3)
where  (.|µ,  2) is a log2-normal distribution density with location parameter
µ and scale parameter  .
In step 1, the estimation of {µT ,  T}g for any given gene g in a subset can be made
separately after estimating {⇡1,i, ⇡2,i}Si=1 for all the samples, where we just use these
most identifiable genes for estimation. By maximizing the likelihood function given
{⇡ˆ1,i, ⇡ˆ2,i}Si=1, l({µT ,  T}g|, {yig, ⇡ˆ1,i, ⇡ˆ2,i}Si=1), for each individual gene g, we obtain
the maximum likelihood estimator of {µT ,  T}g independently. We remove genes
that are estimated with very large  ˆTg, as we consider these genes to be estimated
inaccurately. We then reconstitute tissue-specific expressions of each individual.
Iterated conditional modes
First, using reference samples of N1 and N2 tissue types, we estimated {µN1 ,  N1 , µN2 ,
 N2}Gg=1 through the method of moments. We include these estimates in our objec-
tive likelihood function, then the remaining unknown parameters can be assigned
to two groups: genome-wise parameters, {µT ,  T}Gg=1, and sample-wise parameters,
{⇡1, ⇡2}Si=1. We consider the derivation of the maximum likelihood estimators of
our complete likelihood function as a problem of maximum a posteriori probability
(MAP) estimation with non-informative priors. Then by considering unknown pa-
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rameters as a set of variables, we can use a simple directed acyclic graph to describe
the dependency structure among all the variables in our model. By demoralizing this
directed graph, we obtain a graph to describe the conditional dependencies among
sample-wise and genome-wise parameters, as shown in (Fig. 2.2). For each pair of
genome-wise parameters (considered as variables), we have
{⇡1, ⇡2}i |= {⇡1, ⇡2}j
   {µT ,  T}1, · · · , {µT ,  T}G, {yig}S,Gi,g , for all i 6= j 2 {1, · · · , S}
and similarly for each pair of sample-wise parameters (considered as variables), {µT ,  T}i
|= {µT ,  T}j
   {⇡1, ⇡2}1, · · · , {⇡1, ⇡2}S{yig}S,Gi,g , for all i 6= j 2 {1, · · · , G}. These re-
lationships motivate us to design an optimization method to iteratively derive the
modes of joint density for each pair of genome-wise or sample-wise parameters, con-
ditional on the rest (Besag, 1986).
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Figure 2.2 : Graphical representation of our underlying model. Nodes denote all the
variables representing unknown parameters and observed expression profiles. They
are connected with edges, which suggest conditional dependency structure.
According to our objective in principle, where ⇡1, ⇡2 are constrained between 0
and 1 and µT ,  T are bounded positive, we combined a golden section search and
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successive parabolic interpolations to find a good local maximum in each step (Brent,
1973). Our ICM procedure is organized as follows:
a. Initialize candidate {µ(0)T ,  (0)T }Gg=1
b. In each iteration t = 1, · · · , T
• Step I:
Jointly search the pair {⇡(t)1 , ⇡(t)2 }Si=1 to maximize the likelihood given {µ(t 1)T ,  (t 1)T }Gg=1
w.r.t
f({⇡1, ⇡2}i
  {yig}Gg=1 , {µ(t 1)T ,  (t 1)T }Gg=1) = GY
g=1
f(yig |{⇡1, ⇡2}i, {µ(t 1)T ,  (t 1)T }Gg=1),
8i = 1, · · · , N
(2.4)
• Step II:
Jointly search the pair {µ(t)T ,  (t)T }Gg=1 to maximize the likelihood given {⇡(t)1 , ⇡(t)2 }Si=1
w.r.t
f({µT ,  T}g
  {yig}Si=1 , {⇡(t)1 , ⇡(t)2 }Si=1) = SY
i=1
f(yig
   {⇡(t)1 , ⇡(t)2 }Si=1, {µT ,  T}g),
8g = 1, · · · , G
(2.5)
c. Repeat each iterative steps until the convergence criteria is satisfied (|Lt Lt 1| <
10 5 ⇥ Lt 1).
In these iterative steps of ICM, the complete likelihood is updated by searching
conditional modes. It never decreases at any iteration and the eventual convergence
to the local maximum is guaranteed (Appendix A.1). To find a good local optimum,
we employ random initializations of  (0)Tg , and the initialization of µ
(0)
Tg is given by
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log (3Y¯   exp (µN1g log 2 +  2N1g (log 2)2)  exp (µN2g log 2 +  2N2g (log 2)2)) ( (0)Tg )2(log 2)2/2) log ( 2)
(two-component: log (2Y¯   exp (µN1g log 2 +  2N1g (log 2)2)   ( (0)Tg )2(log 2)2/2) log ( 2)). This is
derived from E(Y ) = E(⇡1)E(N1) + E(⇡2)E(N2) + E(⇡T )E(T ) through assuming
(⇡1, ⇡2, ⇡T ) satisfying Dirichlet distribution with equivalent concentration parameters.
Two-stage estimation
We develop a two-stage estimation procedure for the three-component deconvolu-
tion work. There are a great majority of genes in our test biological data sets with
very similar expression levels across di↵erent cell types (Table 2.1). The selection
of genes that have expression values observationally di↵erent across di↵erent compo-
nents may challenge the inference. Di↵erential expression analysis requires informa-
tion of all those three components, but the T-component is blinded, i.e., we cannot
observe expression patterns from reference profiles for Tig. Also, traditional di↵er-
ential expression analysis is implemented between two components instead of three
and cannot directly quantify the gene expression di↵erence between di↵erent tissues.
Thus, we come out of an intuitive measure for average expression di↵erence among
three components. Through assuming a Dirichlet distribution for proportions, i.e.,
{⇡1, ⇡2, ⇡T}i ⇠ Dir(↵1,↵2,↵3), where ↵0 =
3P
i=1
↵i. The variance for observed tumor
profiles is given by (Goodman, 1960):
V ar(Yg) =
1
↵20(↵0 + 1)
[↵1↵0(↵1 + 1)V ar(N1g) + ↵2↵0(↵2 + 1)V ar(N2g) + ↵3↵0(↵3 + 1)V ar(Tg)
+ ↵1↵2{E(N1g)  E(N2g)}2 + ↵1↵3{E(N1g)  E(Tg)}2 + ↵3↵2{E(N2g)  E(Tg)}2]
(2.6)
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Table 2.1 : Number of genes with di↵erent relationships between di↵erent component
tissues we summarize from datasets in our experimental validation and real data
analysis; we defined µ1 = µ2 by satisfying
µ1
µ2
< 1.1 and µ1µ2 > 0.9.
Unknown Tissue Number of Genes Percentage of Genes
GEO19830:
µliver = µbrain = µlung 19104/31099 61.1%
µliver 6= µbrain = µlung 2432/31099 7.8%
µliver = µbrain 6= µlung 1950/31099 6.3%
µliver 6= µbrain 6= µlung 1260/31099 4.1%
RNA-seq mixed cell line experiment:
µH1092 = µCAF = µTIL 1503/5715 26.3%
µH1092 6= µCAF = µTIL 628/5715 11.0%
µH1092 = µCAF 6= µTIL 979/5715 17.1%
µH1092 6= µCAF 6= µTIL 1227/5715 21.5%
Laser capture microdissected
prostate cancer patient samples:
µTumor = µNormal 32128/32321 99.4%
µTumor 6= µNormal 193/32321 0.6%
Therefore, from the expression of variance for mixed tumor samples, there is a
trade-o↵ between the variance for individual cells and the di↵erence of the aver-
age expression levels between two distinct tissues. We can try to choose genes with
large sample variance for Yig but smaller variance for N1,ig and N2,ig, and imple-
ment a procedure to filter out genes with expression levels that di↵erentiate across
tissue components. We split the whole procedure into two stages that respectively
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estimates proportions for unknown and referenced components over di↵erent gene
subsets. A subset of genes with similar expression pattern for N1 and N2-components
are prepared for degenerating the deconvolution setting from three-component to two-
component. In the first stage, the proportions and distribution parameters for the
unknown component are estimated. Then we substitute those estimated proportions
and parameters into our model, and select a subset of genes that have largest av-
erage di↵erence between N1 and N2 components for deconvolution. This two-stage
approach is arranged as follows.
Stage 1 In this stage, two-component deconvolution is designed for a selected gene
subset. We assume a two-component mixture instead of three. N1 and N2 compo-
nents are combined to focus on estimating ⇡T . We implement it in the following three
steps.
• Step 1: A gene subset is selected with small sample standard deviations of reference
profiles for both N1 and N2-component tissues. Among those genes, we further select
genes with LN1g ⇡ LN2g, where the LN is the sample mean for the log2-transformed
data.
• Step 2: In the selected gene subset, genes with largest sample standard deviations
of Yg are prepared for the next step.
• Step 3: Run DeMixT in two-component setting to estimate µTg,  2Tg and ⇡T .
Stage 2 In this stage, {⇡1}i and {⇡2}i are estimated in the three-component setting
by fixing {⇡T}i with the estimated values from the first stage.
• Step 1: Genes with most di↵erent average reference profiles between N1 and N2
components as well as largest sample standard deviations of Yg are selected.
• Step 2: Run DeMixT in three-component setting over the selected genes to esti-
mate ⇡1 and ⇡2 given ⇡T . Finally, given all the estimated parameters, expression
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levels n1,ig, n2,ig and tig are reconstituted.
2.3.3 R-package
We develop several R functions that are integrated into a freely available R-package
DeMix (http://bioinformatics.mdanderson.org/main/DeMix:Overview) for DeMixT
implementation. DeMixT contain two functions DeMixT.S1 and DeMixT.S2 to run
two-step approaches. DeMixT.S1 estimates tissue-specific proportions for the input
expression data, with the probes/transcripts along the rows and samples along the
columns. The input expression data of each column is required to be labeled with
reference normal profiles or mixed tumor profiles. User can choose if two-stage esti-
mation strategy is employed when a three-component deconvolution is implemented.
DeMixT.S2 estimates the full expression matrices of all consitutents for any input
gene subsets with the given tissue-specific proportions for each samples. Finally, the
function DeMixT combines those two functions to implement the whole pipeline.
DeMixT can be easily used and integrated to existing pipelines for cancer study.
2.4 Simulations
We include two simulation studies to assess the performance of our algorithm on
estimating proportions and distribution parameters respectively for two-component
and three-component. In simulation study, we generated 50 replicates of simulation
data sets for three-component deconvolution and 40 replicates of simulation for two-
component deconvolution.
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2.4.1 Simulation design
For testing three-component deconvolution, we simulate expression profiles of 60
samples for each replicate, consisting of 20 N1-component reference samples, 20 N2-
component reference samples and 20 are mixed tumor samples that needs to be de-
convolved.
We generate a combination of proportions for all these mixed samples, {⇡1, ⇡2, ⇡T}i.
We assign {⇡1}Si with an arithmetic sequence from 0.15 to 0.85 and generate {⇡2}Si
from an uniform distribution with lower limit to be 0.05 and upper limit to be
0.95   ⇡1,i for each samples i. ⇡T is generated by 1   ⇡1   ⇡2. We generated 200
genes. Expression values of N1, N2 and T component tissues for each mixed sample i
and gene g are simulated from a Log2-Normal distribution, where µN1,g ⇠ N(7, 1.5),
µN1,g ⇠ N(7, 1.5), µT,g ⇠ N(7, 1.5) and  N1,g =  N2,g = 0.5,  T,g = 0.5 for the first 25
replicates and  T,g = 1 for the second 25 replicates. Reference profiles are generated
from the same distribution of N1,g and N2,g. Then we average simulated expres-
sion values according to equation 2.1 using assigned proportions as the weights ,and
then generate reference profiles of 20 N1-component and N2-component samples. As
a result, we create 20 mixed samples along with each 20 reference samples for N1-
component and N2-component tissues. We repeat this procedure 50 times.
In testing two-component deconvolution, we simulate data in a similar way. {⇡1}Si is
still generated from an arithmetic sequence from 0.15 to 0.85, then ⇡T,i is calcualted
from 1   ⇡1,i. We also generated 200 genes, and µN1,g and µT,g are generated in the
same way but with  N1,g =  Tg = 0.5. We simulate expression values of 40 mixed
samples with 20 reference samples for N1-component tissues. We prepare 40 repli-
cates for validation.
For purpose of comparison for three-component deconvolution, we implement a Metropolis Hastings
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algorithm for sampling estimated parameters, which is employed by
DeMixBayes for two-component deconvolution in the same package but has crazy
long running time for three-component deconvolution. Uniform priors are given for
{⇡1, ⇡2, ⇡T}Si=1. We use the non-informative independent priors assumed inDeMixBayes
as follows:
µN1g
iid⇠Normal(0, 10, 000), µN2g iid⇠Normal(0, 10, 000), µTg iid⇠Normal(0, 10, 000),
1
 2N1g
iid⇠Gamma(0.001, 0.001), 1
 2N2g
iid⇠Gamma(0.001, 0.001), 1
 2Tg
iid⇠Gamma(0.001, 0.001).
We ran random walk Metropolis-Hastings (RWMH) algorithm for 5000 iterations
and thin the chain every 10 iterations to sample {µN1g ,  N1g}Gg=1, {µN2g ,  N2g}Gg=1,
{µTg ,  Tg}Gg=1 from their full conditional posterior and calculate their posterior means.
2.4.2 Performance evaluation
We evaluate the performance of our method by running DeMixT without two-stage
optimization, that finishes very quickly in two-component setting. For both two-
component and three-component deconvolution, our method has small biases and
high correlations with truth. Esimates for the same true proportion from di↵erent
replicates are highly stable. (Fig. 2.3)
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Figure 2.3 : Boxplots of estimated proportions from DeMixT for 20 samples in all the
simulation replicates. Blue triangles are the truth. The top plot gives ⇡1 estimates
for two-component deconvolution; the bottom plot gives estimates of ⇡1, ⇡2 and ⇡T
for three-component deconvolution.
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Figure 2.4 : Estimated {⇡1, ⇡2, ⇡T} versus truth in three-component deconvolution
simulations through DeMixT and RWMH; red dots denote proportion estimates from
RWMH; blue dots denote proportion estimates from DeMixT.
We compare proportion estimates between those two di↵erent methods for three-
component deconvolution. We compute the Pearson correlation coe cients (COR)
and root-mean-square error (RMSE) between estimates and truth. Our results give
COR above 0.96 and RMSE below 0.05 in the first 25 replicates when  T,g = 0.5. In
the second 25 replicates with larger  T,g, our method still gives a substantially better
COR and smaller RMSE with truth than RWMH (Fig. 2.3 and 2.4). Furthermore
the numerical integration undergirding the two-component model in DeMixBayes is
too computationally intensive to be feasible for the three-component model. The
method of iterated conditional modes can quickly converge and cost no more than
10 hours, while the Bayesian methods require more than one whole week for running
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5000 iterations.
2.5 Experiment Validation
2.5.1 Measures for evaluation
For evaluating the performance of our experiment validation, we first provide and
define several measures we will use in the following discussion.
Concordance correlation coe cient
In our expriment validation, we use the concordance correlation coe cient (COR)
and root-mean-squared error (RMSE) to evaluate the performance of our method
(Lawrence and Lin, 1989). The COR ⇢xy is a measure of the agreement between two
variables x and y and is defined as ⇢xy =
2⇢ x y
 2x+ 
2
y+(µx µy)2 , where µ and  
2 are the
corresponding mean and variance for each variable.
Summary statistics for measure of reproducibility
To assess the stability of the performance across di↵erent scenarios/schemes for dif-
ferent methods, we calculated the sample standard deviations of the estimation error
⇡ˆi   ⇡i across di↵erent scenarios for each observation and then averaged over them
for all the samples. We define a reproducibility statistics as R = 1N
PN
n (
1
T 1
PT
t (✏
t
n 
1
T
PT
t ✏
t
n)
2)
1
2 , where ✏tn = ⇡ˆ
t
n   ⇡n. ⇡ˆtn is the estimated value for the n-th observation
and t-th scenario and ⇡n is the truth. N denotes the sample size and T is the number
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of scenarios. It measures the variations of estimation errors across di↵erent scenarios,
so a method with smaller R has more reproducibility in estimation across di↵erent
scenarios.
A deconvolution tool for comparison: ISOpure
We introduce another published computational deconvolution tool, ISOpure, which
can also jointly estimate tissue-specific proportions and tumor expression profiles for
biospecimens mixed of more than two component tissues (Quon et al., 2013). This
method is similar to DeMixT in assuming a cancer component that does not require
reference profiles. Actually ISOpure and DeMixT are these several only methods that
are able to deconvolve tumor profiles without requiring reference profiles from all the
mixing components. The model assumption in ISOpure is provided as follows:
tn = ancn + (1  an)hn + en (2.7)
tn is tumor profile, cn is the component cancer profile, en is the reconstruction error,
an is the fraction of tumors, and hn =
PR
r=1 ✓n,rbr, which is a weighted average of
available healthy tissue profiles br.
Our method outperforms ISOpure in three aspects: First, ISOpure assumes a convex
combination of reference healthy tissue profiles for the normal profiles. So it does
not explicitly model sample variations for normal profiles, a feature that is necessary
for estimating individual normal profiles. Second, DeMixT provides more reasonable
variation estimates across genes, whereas ISOpure seems to underestimate the gene-
specific variances. Third, in our next discussion, we will show that DeMixT is able to
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provide more accurate estimates of tissue-specific proportions and mean expression
values.
ISOpure has been wrapped into a MATLAB and an R package, so it is convenient to
use it to compare with our method. In our following exploration, we will use ISOpure
as a tool for comparison.
2.5.2 Microarray data analysis of mixed two-component tissues
We first validate our esimation performance for tissue proporitons in the two-component
deconvolution setting. We downloaded two microarray datasets with GSE5350 from
GEO browser. These dat sets mixed RNA sample from isolated 100% Stratagene Uni-
versal Human Reference RNA (A) and 100% Ambion Human Brain Reference RNA
(B) at 75% : 25% ratio and 25% : 75% ratio. Ten mixed samples and five reference
samples processed from two test sites are respectively prepared for deconvolution, and
they are denoted as MAQC1 and MAQC3 (Shi et al., 2006).
We first selected probes with low background noise following a previous procedure.
After running our package on those samples, we compared our proportion estimates
versus truth. The scatter plots show that we can estimate the proportions for all the
samples very well with high COR and low RMSE for both MAQC1 and MAQC3 data
(Fig. 2.5).
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Figure 2.5 : Esimation of proportions of the unknown component for MAQC1 data
and MAQC3 data. Estimated tissue proportions are compared versus true propor-
tions.
2.5.3 Microarray data analysis of mixed three-component tissues
We downloaded datasets GEO19830 (Shen-Orr et al., 2010) from the GEO browser
as benchmark data
(http : //www.ncbi.nlm.nih.gov/geo/browse) to evaluate the performance of DeMixT
on microarray data. This microarray experiment was designed for expression profiling
of samples from Rattus norvegicus with the A↵ymetrix Rat Genome 230 2.0 Array.
The data sets include 30 mixed samples of liver, brain and lung tissues in 10 di↵er-
ent mixture proportions (Table A.1). Three technical replicates were prepared for
each mixture proportion and for the pure liver, brain and lung tissues with purity of
100%. We downloaded the CEL files and used the R package {a↵y} to summarize the
raw probe intensities with quantile normalization but without background correction
according to robust multi-array average (RMA) procedures because background cor-
33
rection is thought to possibly alter the linearity (Liebner et al., 2014; Bolstad et al.,
2003; Irizarry et al., 2003; Carvalho et al., 2007).
To confirm the linearity assumptions for probes that are input into DeMixT, we
required probes prepared for our deconvolution to be measured in the upper quartile
of the log2-transformation data with both N1-component and N2-component tissues.
The linear relationship fits well for our selected probes (green dots) in the experimen-
tal validation of the microarray data, from which the log2-transformed expression
level of at least two tissues measured above 7 for the average level (Fig. A.1). We
filtered out probes with low intensity after checking for the linearity assumption; this
was likely caused by technical measurement errors and background noise.
Linearity testing
Our model relies on an assumption that the tissue-specific expression levels are mixed
linearly. We can check for the validity of this assumption when {⇡1, ⇡2}i are known.
By making simple transformations of equation 2.1, we have
Yig = ⇡1,iN1,ig+⇡2,iN2,ig+(1 ⇡1,i ⇡2,i)Tig ,
8><>: ⇡1,i =
Yig Tig ⇡2,i(N2,ig Tig)
N1,ig Tig
⇡2,i =
Yig Tig ⇡1,i(N1,ig Tig)
N2,ig Tig
(2.8)
Thus, we created scatter plots with a regression line to compare Yig   Tig   ⇡2,i(N¯2,g   Tig)
with N¯1,g   Tig and Yig   Tig   ⇡1,i(N¯1,g  Tig) with N¯2,g   Tig, where the sample mean
for N¯1,g(e.g. Liver), N¯2,g(e.g. Brain) and T¯g(e.g. Lung) were used instead of each
N1,ig, N2,ig and Tig.
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Estimation of tissue proportions
The samples in the data set GSE19830 are all mixtures of pure liver, brain and
lung tissues in specific ratios. We used these samples with 100% purity as pure N1-
component, N2-component and T -component tissue samples. The deconvolution for
the remaining 30 mixed samples was performed in three di↵erent schemes, respectively
assuming liver, brain and lung tissues to be the unknown T -component tissue. We
implemented DeMixT on those mixed samples and evaluated the estimation perfor-
mance for tissue proportions and expression levels. In the first stage of the two-stage
estimation, we selected 250 probes to be deconvolved on DeMixT after running 10
iterations, and in the second stage, we selected 200 probes. For comparison purposes,
we ran ISOpure to estimate the tissue proportion for the T -component tissue.
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Figure 2.6 : Consistency in estimation of rat tissue proportions. Scatter plots of esti-
mated tissue proportions against true tissue proportions when either the liver, brain,
or lung tissue is assumed to be the unknown tissue; blue rectangles representDeMixT
estimates when liver tissue is assumed to be unknown; blue circles representDeMixT
estimates when lung tissue is assumed to be unknown; blue rectangles represent
DeMixT estimates when brain tissue is assumed to be unknown; black crosses repre-
sent ISOpure estimates.
For all those three deconvolution schemes aforementioned, DeMixT present high
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correlations between estimates and truth for {⇡1, ⇡2, ⇡T}Si=1 and RMSE of estimates
across these three scenarios were all reported less than 0.15 (Table 2.2 and Table 2.3).
In Table 2.3 and Figure 2.6, DeMixT was reported with much smaller RMSE below
0.1 for the unknown T-component than ISOpure when brain and lung are assumed
to be the T-component tissues. While DeMixT was observed with larger RMSE
when liver is assumed to be unknown (Fig. 2.6), the performance across all the three
scenarios are consistent where liver was reported with small under-estimation, brain
with small over-estimation and lung with accurate estimation (Table 2.4).
Table 2.2 : Concordance correlation coe cients between estimated proportions and
true proportions in the GSE19830 data set. The 95% confidence interval is given in
the bracket.
Estimated Tissue Brain Lung Liver Average
DeMixT 0.88 0.95 0.74 0.86
(Brain Unknown) (0.80, 0.93) (0.91, 0.97) (0.61, 0.83)
DeMixT 0.84 0.97 0.75 0.85
(Lung Unknown) (0.71, 0.91) (0.95, 0.98) (0.63, 0.84)
DeMixT 0.77 0.96 0.74 0.82
(Liver Unknown) (0.65, 0.86) (0.94, 0.97) (0.62, 0.83)
ISOpure 0.69 1 0.72 0.8
(Brain Unknown) (0.55, 0.79) (1.00, 1.00) (0.58, 0.81)
ISOpure 0.97 0.74 0.84 0.85
(Lung Unknown) (0.94, 0.99) (0.61, 0.83) (0.75, 0.90)
ISOpure 0.93 0.98 0.98 0.96
(Liver Unknown) (0.88, 0.96) (0.96, 0.99) (0.96, 0.99)
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Table 2.3 : Root mean squared errors (RMSEs) between estimated proportions and
true proportions in the GSE19830 data set.
Estimated Tissue Brain Lung Liver Average
DeMixT 0.08 0.06 0.13 0.09
(Brain Unknown)
DeMixT 0.1 0.05 0.13 0.09
(Lung Unknown)
DeMixT 0.12 0.05 0.13 0.1
(Liver Unknown)
ISOpure 0.18 0.02 0.16 0.12
(Brain Unknown)
ISOpure 0.04 0.14 0.11 0.1
(Lung Unknown)
ISOpure 0.07 0.04 0.04 0.05
(Liver Unknown)
Estimation of tissue-specific expression
Corresponding to each scheme we performed deconvolution, we also estimated tissue-
specific expression levels for the whole probe set throughDeMixT by fixing {⇡1, ⇡2, ⇡T}i
with the estimates of tissue proportions. Expression levels for each probe were es-
timated independently when the tissue proportions were given. Both DeMixT and
ISOpure yielded accurate estimations of the mean expression values when deconvolv-
ing the gene expression values (Fig. 2.7).
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Figure 2.7 : MA plots of estimated tissue-specific expression between DeMixT and
ISOpure in the GSE19830 data set. DeMixT provides accurate estimation of tissue-
specific expression. MA plots compare the mean values of deconvolved expression
levels across genes forDeMixT vs. ISOpure, DeMixT vs. observed samples, and
ISOpure vs. observed samples when either liver, lung or brain tissue is assumed to
be the unknown component.
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Table 2.4 : Calculated value of summary statistics of reproducibility for estimation
of component proportions across di↵erent scenarios in the GSE19830 data set and
RNA-seq data from mixed cell line experiment. H1092: lung tumor adenocarcinoma;
CAF: cancer-associated fibroblasts; TIL: tumor infiltrating lymphocytes.
Estimated Tissue DeMixT ISOpure
Brain 0.03 0.10
Lung 0.03 0.08
Liver 0.03 0.07
H1092 0.03 0.39
CAF 0.02 0.40
TIL 0.02 0.20
2.5.4 RNA-seq mixed cell line experiment
The experiment is designed to validate the performance of DeMixT on RNA-seq data
sets. The expression scale of raw level microarray is similar to that of sequencing
data. Although our log2-normal distribution assumption is sourced from microarray
data, the concordance between sequencing data and microarray data on transcript
abundance suggests that it can be directly applied to RNA-seq data (Wang et al.,
2014). We mixed mRNA from cell lines of lung adenocarcinoma in humans (H1092),
cancer-associated fibroblasts (CAFs) and tumor infiltrating lymphocytes (TIL) in
di↵erent cell proportions to generate 23 samples with two replicates for each sample
(Table A.2). The RNA amount of each tissue in the mixture samples was calculated
on the basis of real RNA concentrations tested in our collaborators’ lab. We pre-
pared three pure cell line samples with cell proportions of 100% for lung tumor, pure
fibroblasts, and pure lymphocytes. Each sample was generated with two replicates.
39
The following pipeline was devised to obtain gene expression counts for these sam-
ples. At the onset, raw reads generated from pair-ended sequencing were mapped to
the genome reference. The mapped reads were cleaned and sorted by their names to
give the reads random ordering. For short-read alignment, we applied the R pack-
ages GenomicFeatures and GenomicRanges and used the reference human genome
h19 to generate a reference table. We used the function findOverlaps to obtain gene
expression counts for all the samples. Then we input the gene expression counts of
the mixed samples and pure samples from every two components of tissue to validate
the deconvolution.
Estimation of tissue proportions
We treated every replicate of a sample as an individual sample, so we had 46 mixed
tumor samples to deconvolve. Each type of mixed tissue was assumed to be the un-
known T type tissue. Before deconvolution, we scale-normalized the data matrix and
discarded the genes that contained a count of zero. In both stages of our optimiza-
tion, we selected 250 genes for deconvolution in the respective two-component and
three-component settings. We evaluated the performance of DeMixT on RNA-seq
data the same way by comparing it with the true mRNA proportions and estimates
from ISOpure.
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Figure 2.8 : DeMixT yields accurate estimation of proportions of RNAseq data gen-
erated from mixed lung cancer cell lines. Scatter plots of estimated tissue proportion
against true tissue proportion when either lung tumor or fibroblast is assumed to
be the unknown T-type tissue; blue crosses represent DeMixT estimates when lung
tumor cell is assumed to be unknown; blue rectangles represent DeMixT estimates
when fibroblast cell is assumed to be unknown; black crosses and rectangles represent
ISOpure estimates.
When H1092 and CAFs are considered as the unknown component, DeMixT pro-
vides expected estimates with tighter COR and remarkably smaller RMSE (< 0.1)
with the true proportions compared with ISOpure (Table 2.5 and Table 2.6). Pro-
portion estimates given by DeMixT are consistent when di↵erent components were
treated as unknown in our experiments (Fig. 2.8). In our experiment, the truth
mRNA proportions of TIL are all very small, so it is too di cult to detect such
weak signals without reference profiles for TIL. When TIL is considered as the T -
component, DeMixT and ISOpure are both reported with poor performance by over-
estimating the proportions of immune tissues (Fig. 2.9). When the proportions of
one component tissue are remarkably low(< 5%) for all the samples, mixed samples
are artifacts of three-component mixtures without any reference information for the
low proportion component, because this component could be recognized as noises.
Deconvolution algorithm will fake its information for the unknown component, ex-
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cept that it has much higher or lower expression values for all the selected genes than
that of other components.
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Figure 2.9 : Estimated Tissue proportion versus truth proportion when cell type
H1092 is the unknown T -component tissue; Red dots represent DeMixT estimates;
Blue dots represent ISOpure estimates.
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Table 2.5 : Concordance correlation coe cients between estimated proportions and
true proportions in RNA-seq data from mixed cell line experiment. The 95% confi-
dence interval is given in the bracket. We use H1092, CAF and TIL to respectively
denote lung tumor adenocarcinoma, cancer-associated fibroblasts and tumor infiltrat-
ing lymphocytes.
Estimated Tissue Lung Tumor Fibroblast Immune Average
(H1092) (CAF) (TIL)
DeMixT 0.99 0.98 0.12 0.7
(H1092 Unknown) (0.98, 0.99) (0.96, 0.99) (0.03, 0.20)
DeMixT 0.94 0.99 -0.02 0.64
(CAF Unknown) (0.90, 0.96) (0.98, 0.99) (-0.10, 0.06)
ISOpure 0.81 0.14 0.03 0.33
(H1092 Unknown) (0.73, 0.87) (0.03, 0.25) (0, 0.07)
ISOpure 0.28 0.62 -0.04 0.29
(CAF Unknown) (0.18, 0.37) (0.51, 0.71) (-0.09, 0)
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Table 2.6 : Root mean squared errors between estimated proportions and true pro-
portions in RNA-seq data from mixed cell line experiment.
Estimated Tissue Lung Tumor Fibroblast Immune Average
(H1092) (CAF) (TIL)
DeMixT 0.03 0.04 0.07 0.05
(H1092 Unknown)
DeMixT 0.07 0.03 0.06 0.05
(CAF Unknown)
ISOpure 0.14 0.37 0.26 0.26
(H1092 Unknown)
ISOpure 0.42 0.26 0.22 0.3
(CAF Unknown)
Estimation of tissue-specific expression
For these two schemes we are able to accurately estimate proportions, we estimated
tissue-specific expressions for all the genes without zero count by substituting esti-
mates of {⇡1, ⇡2, ⇡T}Si=1. We evaluate deconvolved expression profiles in the log2-
transformed scale.
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Figure 2.10 : MA plots of estimated tissue-specific expression between DeMixT and
ISOpure in mixed cell line RNA-seq data. Improperly estimated probes from DeMixT
are removed. DeMixT provides accurate estimation of tissue-specific expression. MA
plots compare mean value of deconvolved expression profiles for DeMixT vs. ISOpure,
DeMixT vs. observed samples, and ISOpure vs. observed samples when either lung
tumor or fibroblast cell is assumed to be the unknown component.
It shows high correlation between mean values of deconvolved expression profiles
and the measured true mean values (Fig. 2.10). Much lower RMSE demonstrates
better performance of DeMixT for deconvolving sequencing data, and it validates the
use of our model on sequencing data.
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2.6 Real Data Analysis
2.6.1 Microarray study of laser capture microdissected prostate cancer
patient samples
We applied DeMixT to real tumor samples and examined its performance. Laser-
capture microdissection was used to separate stromal and tumor tissues from prostate
cancer samples, providing a gold-standard validation data set. We collected a cohort
of samples from prostate cancer patients, which consist of 25 samples of isolated tu-
mor tissues, 25 samples of isolated stromal tissues and 23 mixture samples. Radical
prostatectomy specimens were annotated in detail by pathologists, and regions of
interest were identified that corresponded to the benign epithelium, PIN and tumor,
each with its surrounding stroma. These regions were laser-capture microdissected
using ArcturusXT system (Life Technologies). Additional areas of admixed tumor
and adjacent stromal tissue were taken. RNA was extracted by AllPrep (Qiagen)
and quantified by RiboGreen assay (Life Technology). RNA labeling was performed
using SensationPlus FFPE method (A↵ymetrix) and hybridized to A↵ymetrix Gene
Array STA 1.0. For the analysis, we used a subset of RMA normalized gene expression
data corresponding to tumor, tumor-adjacent stromal tissue and an admixed region.
We tested deconvolution in these settings when the tumor is unknown and the stro-
mal tissue is unknown. An explicit calculation of the average expression di↵erence
between the two components |N   T |, where N and T are sample means of normal
and tumor tissues, shows there is just a small portion of probes with di↵erential ex-
pression. To validate our deconvolution method, we pre-selected a subset of the top
80 di↵erentially expressed probes with the largest |N   T | and used this pre-selected
probe set for deconvolution.
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Result analysis
After preselecting a subset of probes for deconvolution, we ran an analysis with either
tumor or stromal components treated as unknown. We found that DeMixT obtained
concordant estimates of tumor purity under the two conditions (r = 0.87) while
ISOpure did not (r = 0.36) (Fig. 2.11). DeMixT also tended to provide mean
component-specific expression levels with much lower biases than ISOpure (Fig. 2.12)
and yielded standard deviation estimates that were close to those from the dissected
tumor samples (Fig. 2.13).
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Figure 2.11 : Scatter plot of estimated tumor proportion when the tumor proportion
is unknown against those when the stromal proportion is unknown in prostate cancer
patient samples; estimations ofDeMixT (blue) are compared with those of ISOpure
(black).
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Figure 2.12 : MA plots of estimated tissue-specific expression between DeMixT and
ISOpure in a microarray study of prostate cancer samples. MA plots compare mean
value of deconvolved expression profiles for DeMixT vs. ISOpure, DeMixT vs. ob-
served samples, and ISOpure vs. observed samples when either tumor or stromal
tissue is assumed to be the unknown component. We used a filtered probe subset
with the most di↵erential expression between tumor and stromal tissues and smaller
expression variation for known tissues from 23 lung cancer patient samples.
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Figure 2.13 : Density plot comparing sample standard deviations between decon-
volved expression profiles of subset probes for DeMixT and ISOpure when tumor
tissue is assumed to be the unknown component; with measured expression profiles
of isolated tumor tissues.
2.6.2 Immune infiltration in virus-associated tumors
Infection with the human papillomavirus (HPV) plays a critical role in cervical cancer
and likely in a subset of head and neck squamous cell carcinoma (HNSC). HNSC
tumors with HPV+ test results are believed to be clinically distinct from tumors
with HPV- test results. A recent study has demonstrated that the infiltration of
immune cells, both lymphocytes and myelocytes, is positively associated with viral
infection in virus-associated tumors, where the high viral infection group corresponds
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with high rates of immune infiltration (Li et al., 2016). To validate this finding,
we downloaded HNSC RNA-seq data from the TCGA data portal (Network et al.,
2015a) and ran DeMixT to estimate the proportions of tumor cells, stromal cells and
immune cells.
Data analysis
We devised an estimation algorithm for estimating the immune cell proportions
(Fig. 2.14) and downloaded RNA-seq data for head and neck squamous cell car-
cinoma (HNSCC) from The Cancer Genome Atlas (TCGA) data portal (https :
//tcga  data.nci.nih.gov/tcga/). We also collected the infection information of hu-
man papillomavirus (HPV) for HNSCC samples, so that we have the positive infected
group and the negative infected group for each cancer. After removing mislabeled
samples, we have 287 samples (44 normal, 243 tumor) for HNSCC. We scale normal-
ized the expression data for each cancer type and filtered out genes with zero count
in any sample.
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44 matched normal samples 243 matched tumor samples
training sets: 9 tumor samples
(stromal score > 0 & immune score < -2)
two-component DeMix-T
9 purified tumor samples
three-component DeMix-T
immune component of 234 
samples
test sets: 234 tumor samples
Figure 2.14 : Data analysis workflow for validation of immune infiltration in HNSC
tumors. We assigned 43 tumor samples in the training set and 230 tumor samples
in the test set. We use DeMixT in a two-component setting and a three-component
setting in di↵erent steps.
We designed a pipeline to prepare the expression profiles of pure tumor tissues for
deconvolution. That process can be separated into two steps and we filtered out dif-
ferent gene subsets to run two-component or three-componentDeMixT in each step.
We downloaded stromal and immune scores from single-sample gene set enrichment
analysis (ssGSEA) for all the TCGA samples (Network et al., 2015a) and used them
to help us group the samples. We pre-selected 9 tumor samples with positive stromal
scores (> 0) and negative immune scores (<  2), which implies enriched stromal
tissues with low immune infiltration. We considered these samples as a mixture of
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just stromal and tumor tissues and ran the two-component deconvolution algorithm
in DeMixT to obtain deconvolved expressions of pure tumor tissues for each individ-
ual sample. deconvolved expression profiles from the genes that have small variations
were combined as the input for deconvolution of all the remaining tumor samples.
In the next step, all the remaining tumor samples were deconvolved using expression
matrices of normal samples and reconstituted tumor component from the first step.
With estimated tumor, stromal and immune proportions for each cancer type, we
made several analyses by comparing them between the positive and negative virus
infection groups.
Result analysis
We compared the estimated immune proportions in the test set between the tumor
groups, one with positive and one with negative HPV infection results. The boxplot
(Fig. 2.15) and the density plot (Fig. 2.16) show that tumor samples with HPV+ test
results had systematically higher immune component proportion estimates than those
with HPV- test results (P = 0.004). We also analyzed the deconvolved expressions
of three important immune cell-related genes, CD4, CD8A and HLA-DQB1 that are
expressed in the immune cells. This result (Fig. 2.17) shows that deconvolved expres-
sion levels are higher in the immune component than in the other two components
for those three genes.
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Figure 2.15 : Box and whisker plots of immune proportions HNSC samples in the
test set display di↵erences between HPV + (red) and HPV   (white) samples
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Figure 2.16 : Density plot of immune proportions for tumor samples in test set with
HPV test: Red line is for estimated immune proportions of tumor samples with
positive HPV test; blue is for those with negative HPV test. From the probability
density plot, we observe that the tumor samples with HPV-positive test results have
more mass in the region of high immune proportion than those with HPV-negative
test results.
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Figure 2.17 : Density plot of log2-transformed deconvolved expressions for three im-
portant genes for immune cells. Red curve represents CD4; green represents CD8A;
and blue represents HLA-DQB1. Solid lines are for the immune component; dot-
ted lines are for the stromal component; and long dashed lines are for the tumor
component.
2.7 Discussion
Cellular heterogeneity is an important feature of human cancer, which strongly influ-
ences downstream analysis based on transcriptomes. Expression profiling technique
has demonstrated its potential to disclose useful information for cancer prognosis.
Most of the methods developed for deconvolution have their limitations, and do not
include tumor infiltrating immune cells into their work, when it is of great significance
to understand cellular heterogeneity in terms of the interaction between tumors and
immune system.
In this work, we have presented a novel statistical method for dissecting tumor mix-
tures on the gene expression level, which provides a fast and accurate approach to the
deconvolution of tumor specimens into two or three components. Our method allows
us to estimate both cell-type-specific proportions and reconstitute patient-specific
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gene expression levels at the same time with little prior information. Key features of
our work that di↵er from previous deconvolution methods are as follows.
(i) We developed a computational tool, DeMixT, that deconvolves the sample con-
texture without any prior information on tissue proportions and tumor-specific ex-
pression; the input data are gene expression levels for tumor specimens and refer-
ence profiles. Reference profiles can be derived from historical patient data or other
pipelines. We do not require reference profiles for all mixing components, and allow
the information of one constituent to be unknown.
(ii) It is not necessary to incorporate any cell-type-specific reference genes or borrow
any other gene subset identification methods for DeMixT. DeMixT solves the decon-
volution problems with steps all through computation. We also propose a two-stage
procedure to select the identifiable genes between di↵erent tissue components in dif-
ferent steps, and therefore improve the estimation performance.
(iii) Our model follows from the biological prospective by making use of the normality
of log2-transformed expression data and linearity of raw measured data. DeMixT is
able to deconvolve expression data from tumor specimens into both two component
tissues and three component tissues. We incorporate the immune infiltration into the
deconvolution model. It accurately estimates tissue-specific proportions and recon-
stitutes expression profiles.
(iv) In the validation of immune infiltrations in virus-associated tumors, we have
shown that DeMixT can be applied for deconvolution of samples with immune in-
filtration by combining two-component and three-component DeMixT with clinical
information.
In conclusion, we develop a statistical modeling that has unique advantages over in
silico deconvolution of bulk tumors and helps to resolve the bottleneck arising from
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sample heterogeneity in cancer genomic studies. One potential limitation of DeMixT
is the direct inclusion of the immune infiltrating component by integrating all immune
cell subtypes, which may require additional clinical information and need to be pre-
processed in some case. The other concern is performing deconvolution on datasets
with fewer components than the number of components it is assumed. To give so-
lutions to this problem, we need other resources to help us to identify a reasonable
number of major component tissues just as what we did in the HNSCC experiment.
In our exploration following deconvolution work, we find an important problem that
may significantly a↵ect deconvolution performance. In the genomic data, there might
be a small portion of genes/probes that can contribute to deconvolution. Introducing
redundant noisy genes, which are non-identifiable by deconvolution model, may pre-
vent the unambiguous determination of proportion estimation. Moreover, because all
the existing in silico deconvolution tools assume independently distributed expres-
sion pattern for each gene, the functional relationship among genes is also a factor to
bias estimation. We are under study of gene’s identifiability for deconvolution, where
identifiability indicates the di↵erence of expression patterns between di↵erent compo-
nents is significantly larger than their variations within each component. Inclusion of
genes with large variations of expression profile but small di↵erence among di↵erent
components is detrimental to deconvolution. Di↵erential expression analysis based
on observed tumor profiles cannot discover the true di↵erence between hidden com-
ponents. Defining a distance metric of expression profiles across multiple components
is also a hard job. Therefore, it will be necessary to develop a benchmark for feature
selection before deconvolution.
In our future work, we will focus more on developing statistical methods to extend
the deconvolution algorithm to include more number of component tissues. It will
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make it possible to give proportion estimates for each leukocyte subset of tumor infil-
trating immune cells. We also want to have a deconvolution model in the future that
accounts for the correlation between genes, which reflect real biological activity that
a↵ects tumor-normal interaction.
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Chapter 3
Bayesian Edge Regression for Undirected
Graphical Models Accounting for Biological
Heterogeneity
3.1 Abstract
Current work for constructing graphical models for multivariate data does not take
into account the subject specific information, which can bias the conditional inde-
pendence structure in heterogeneous data. According to our discussion in the first
two chapters, tumor samples are inherently heterogeneous with contaminated mix-
tures of normal and tumor cells. Ignoring the cellular heterogeneity in tumors and
modeling the population-level genomic graphs, may inhibit the discovery of the true
tumor graph, which would be attenuated towards the normal graph. In this chapter,
we propose a novel edge regression model for undirected graphs, which incorporates
subject-level covariates to estimate the conditional dependencies. Our model allows
undirected networks to vary with the exogenous covariates and is able to borrow
strength from di↵erent related graphs for estimating more robust covariate-specific
graphs. Bayesian shrinkage algorithms are presented to e ciently estimate and in-
duce sparsity for generating subject-level graphs. We demonstrate the performance
of our method through simulation studies. We apply our method to several real-world
datasets, including cytokine measurements from blood plasma samples from hepato-
cellular carcinoma (HCC) patients and normal controls.
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3.2 Introduction
Graphical models, which characterize the conditional dependency structure among
random variables, have gain more and more popularity in genomic studies to build
the networks between di↵erent biological units, including genes and proteins. We
focus on undirected graphical models, where nodes index random variables and edges
represent the global conditional dependency between the variables corresponding to
connected nodes (Lauritzen, 1996). A popular tool in studying undirected graph is
Gaussian graphical models, which corresponds the absence of an edge to a zero entry
in the precision (or concentration) matrix of multivariate Gaussian distribution, so it
is also well-known as the problem of covariance selection (Dempster, 1972). Although
a great amount of literature is provided for covariance selection, a standard formu-
lation of this problem restricts observations to be drawn from the same distribution
(e.g. Gaussian). However, the complexity of extraneous factors in genomic studies
undermines this assumption. For example, there has been much progress in the study
of group-specific graphical models to describe dependency for observations collected
in distinct classes (Peterson et al., 2015; Danaher et al., 2014). Ni et al. (2017) con-
structed directed acyclic graphs (DAG) for generalizing those group-specific factors
by investigating non-static graphs a↵ected by extraneous factors (e.g. patient-level
prognostic biomarkers), which are allowed to be categorical or continuous, in ge-
nomic studies. Ni et al. (2017) proposed the concept of graphical regression, which
formulated the inference of graphs changed by extraneous factors with a problem of
regressing the graph structure on those exogenous covariates. However, he just solved
this problem in a directed acyclic graph (DAG) setting, and it is still challenging in
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estimating undirected graphs because of their more complicated conditional indepen-
dence properties (Ni et al., 2017).
As the primary application of graphical models in genomic analyses, co-expression or
regulatory networks - genes/proteins that interact with each other - may be poten-
tially biased by environmental factors (Luscombe et al., 2004). Our research is mo-
tivated by modern cancer research, where-in tumor heterogeneity has been shown to
bias the downstream analyses after global expression profiling of tumors (Farley, 2015;
Junttila and de Sauvage, 2013). The tumor samples drawn from patients exhibit het-
erogeneity on the cellular level, because the epithelium-derived tumor interacts with
the microenvironment (normal tissue), which mostly comprises non-cancer cells and
surrounding stroma, during the development and progression of cancer. Those non-
cancer cells contaminate gene expression profiles and add noises to detected molecular
characteristics for solid tumors. We can model the transcriptional profile of a single
clinically derived tumor sample as a mixture of its constituting cancerous ‘tumor’
and non-cancerous ‘normal’ component (Heppner and Miller, 1983; Liotta and Pet-
ricoin, 2000). Tumor purity, which is the proportion of cancerous tissues, measures
the degree of normal contamination and varies widely among solid tumor samples
pre-selected for genomic analyses. It adds major confounding factors resulting from
tumor-normal interactions to bias the final results (West et al., 2010; Bachtiary et al.,
2006). For assays run on solid tumor samples, the sample will often be a mixture
of normal and tumor cells that cannot practically be separated from each other. By
estimating and accounting for the tumor purity for each sample we can gain power
for detecting tumor-normal di↵erences. In other settings, heterogeneity can also be a
factor. Although a majority of deconvolution methods are provided for estimating tu-
mor purity from mixed tumor samples, they cannot accurately recover co-expression
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patterns for di↵erent compartments in solid tumors and maintain the dependency
structure across molecular units due to their assumption of independently expressed
genes (Yadav and De, 2015). We are interested in studying the common and di↵eren-
tial dependency structure within tumor and normal component from clinically derived
tumor samples, where 100% pure tumors are rarely collected. Current approaches for
this study just consider those mixed tumors with a population of reference normal as
two di↵erent classes of samples, which cannot recover the network for pure tumors.
In this sense, graphical regression provides us with coherent inferential framework
on how the structure of tumor network varies with tumor purity, and finally helps
us to recover a pure ‘normal graph’ (network structure for non-cancerous tissues)
and a pure ‘tumor graph’ (network structure for cancerous tissues) from those learnt
subject-level networks by substituting tumor purity with 0% and 100%.
3.3 Existing methods for undirected graphical models
The use of G-Wishart distribution as a conjugate prior for the precision matrix and
penalized likelihood (Friedman et al., 2008; Huang et al., 2006) for the sparsity con-
trol are the two major traditional means of inference for Gaussian graphical models.
Recently developed regularization methods through neighborhood selection, which im-
plement penalized regression per node over all the other nodes, provide us with dif-
ferent approaches for inference of undirected graphs (Meinshausen and Bu¨hlmann,
2006). Several methods using a joint sparse regression and Bayesian shrinkage prior
have been suggested for new benefits based on neighborhood selection (Leday et al.,
2015; Peng et al., 2012). There also have been several attempts to model undirected
graphs with a similar flavor as graphical regression. Ho↵ and Niu (2012) proposed
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a covariance regression model by regressing covariance matrix over explanatory vari-
ables for factor analysis. Zhou et al. (2010) and Kolar and Xing (2009) developed
dynamic undirected graph models varying with time. Cheng et al. (2014) modeled
multivariate binary data using an Ising model to study the change of dependency with
covariates. Liu et al. (2010) proposed an algorithm Graph-optimized classification and
regression trees to partition the covariate space and estimate the graph within each
partition subspace. However, Cheng et al. (2014) reported that this model is lack of
interpretation of the relationship between graphical models and covariates, and it is
unstable since graphs constructed for close covariates are not necessarily similar. A
machine learning method proposed by Kolar et al. (2010) applied a penalized kernel
smoothing approach and allowed the precision matrix to change with covariates, but
this method is limited by ignoring the intrinsic symmetry of elements in precision
matrix, which may result in contradiction for neighborhood selection and subsequent
interpretation.
In this work, we developed a Bayesian edge regression (ER) approach for undirected
graphical models. Similar in spirit to Ni et al. (2017), we define an edge-specific con-
ditional precision function to allow the edge strength for undirected graphical models
to vary with the exogenous covariates. This function is linked with the estimation of
element in the precision matrix through a joint regression model, hence constraining
the elements corresponding to the same pair of nodes to be exactly same and guar-
anteeing the symmetry of estimated precision matrix. This subsequently helps us to
better interpret the relationship between the graph structure and covariates and also
allows predicting graph structure for new observations. The use of adaptive Bayesian
shrinkage prior induces the local shrinkage of edge strength with a global shrinkage of
the regularizing parameter over exogenous covariates across di↵erent edges. In doing
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so, we impose two-level shrinkage on the edge strength and exogenous covariates. We
combine a scheme of edge selection that allows coherent multiplicity controls of the
expected global Bayesian false discovery rate (FDR). We discuss the parameterization
of precision function and provide several parameterization solutions depending on the
scientific and inferential context. Finally we illustrate the application of our model
to infer networks in heterogeneous tumor samples and group specific observations
through simulations and case studies using cancer genomic and proteomic data. We
apply this method to a prostate cancer data set and a liver cancer cytokine study to
estimate blood plasma cytokine networks induced by hepatocellular carcinoma and
those from normal controls while accounting for biological heterogeneity.
The rest of chapter is structured as follows. In Section 3.4, we provide a formal de-
scription of edge regression with several theoretical properties for undirected graphical
models. Then we present our models with sampling scheme and posterior inference
technique. We present our simulation studies in Section 3.5 and include case studies
on prostate cancer samples and blood plasma samples from hepatocellular carcinoma
with application of our method in Section 3.6. Section 3.7 concludes this chapter
with discussion.
3.4 Methods
3.4.1 Edge regression
A graphical model for a random p-vector Y is defined by a tuple GY = {G,P(Y )},
where G is a graph and P(Y ) denotes its associated distribution. G = (V,E) repre-
sents conditional independence structure among random variables by specifying a set
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of nodes V = 1, 2, 3, · · · , p and a set of edges E 2 V ⇥ V . Each node in the graph G
corresponds to a random variable in Y . In an undirected graph, we have undirected
edges E, where (i, j) 2 E if and only if (j, i) 2 E. For example, a Gaussian graphical
model is defined by assuming P(Y ) is a Gaussian distribution with mean µ 2 Rp and
covariance matrix ⌃ 2 Rp⇥p.
Yn ⇠ N (µ,⌦ 1), n = 1, · · · , N (3.1)
, where Yn is the observed data and⌦ = ⌃ 1 2 Rp⇥p is the inverse covariance matrix
(a.k.a precision matrix or concentration matrix). In Gaussian graphical model, ⌦ is
a symmetric positive definite matrix and we denote the precision matrix by (!ij)p⇥p.
If !ij = 0, then the random variable i and j are conditionally independent given all
the other variables of Y , which indicates there is no edge in G between node i and
node j. Therefore the parameterization of precision matrix ⌦ can be bridged with
the construction of the conditional independence structure in the graph G. This is
well-known as the covariance selection model.
In our proposed edge regression model, given another q-dimension random vector
X = (x1, · · · , xq)T , we consider GY(X) = {G(X),P(Y |X)} and the precision ma-
trix for each observation Yn given X = xn is a function of X, reflecting that the
conditional independence structure is able to vary from observation to observation
over di↵erent realizations of X. In the following discussion, we use the term exoge-
nous covariates to defineX. We denote the precision matrix dependent onX through
⌦(x) so its element !ij(X). !ij(X) is specific to the edge (i, j) (equivalently, (j, i))
and can be allowed to be a linear relationship. We formally state a lemma of edge
regression for covariance selection problem.
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Lemma 1 (FUNCTIONAL COVARIANCE SELECTION RULE) Assuming Y has
a multivariate Gaussian distribution given exogenous covariates X with a precision
matrix ⌦(X). Y i |= Y j|Y  (i,j),X , !ij(X) = 0
Lemma 1 follows from the covariance selection rule when a set of exogenous covariates
X is given. Following Ni et al. (2017), these special cases of edge regression are
provided:
(1) If X = ;, then edge regression model reduces to the case of the ordinary undi-
rected graphical model.
(2) If X is a set of discrete covariates (e.g., binary/categorical), then edge regression
model reduces to the problem of estimating group-specific graphical models.
3.4.2 Regression model for undirected graphs
In this section, we introduce a sparse regression model for implementation of edge
regression. From now on we assume the µ = 0 for simplicity. Denote the par-
tial correlation between random variable Y i and Y j by ⇢ij(1  i 6= j  p), where
⇢ij =   !ijp
!ii!jj
. Hence, from the covariance selection rule, the edge (i, j) 2 E is equiv-
alent to the partial correlation ⇢ij 6= 0. A well-known lemma implies that when yi
(1  i  p) is expressed in a linear regression form ofPj 6=i  ijyj+✏i,  ij =  (!ij/!ii)
and ⇢ij can be represented as sign( ij)
p
( ij ji). We can extend this lemma to a case
of edge regression by including the exogenous covariatesX into the regression method.
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Lemma 2 For 1  i  p, considering predicting yi from other variables y i given ex-
ogenous covariatesX = x with a varying-coe cient model, we have yi =
P
j 6=i  
ij(x)yj+
✏i, such that ✏i is uncorrelated with y i given X = x if and only if the optimal pre-
diction rule gives  ij(x) =  !ij(x)!ii(x) = ⇢ij(x)
q
!jj(x)
!ii(x) , where !
ii(x) and !ij(x) re-
spectively correspond to the o↵-diagonal and on-diagonal element of ⌦(x). Hence,
⇢ij(x) = sign( ij(x))⇥ p ij(x) ji(x). Additionally, var(✏i) = 1/!ii(x).  ij(.) is a
conditional precision function (CPF) that defines ⇢ij through X.
Lemma 2 is also self-evident when the partial correlation is calculated givenX. From
Lemma 2, X changes the partial correlation ⇢ij as well as the regression coe cients
of yi over yj through the function  ij(.). In this sense,  ij(.) can be fitted to charac-
terize the conditional dependency structure for a subject-level graph givenX. Under
this setting, the covariance selection problem for a subject-level graph can be con-
verted to a feature selection problem for regression with varying coe cients (Hastie
and Tibshirani, 1993), i.e., the sparsity structure of undirected graph can be learnt
through a sparse regression. When we apply edge regression, the shrinkage of  ij(x)
to exact zero can be realized through the shrinkage of each coe cient in the function
of  ij(.). Although the whole precision matrix is currently allowed to vary with X,
for model parsimony and simplicity, we assume the on-diagonal element !ii constant
across di↵erent X due to our primary interest on the relationship between the edge
structure (determined by o↵-diagonal element !ij) and X. Hence, the study of how
exogenous covariates a↵ect edge selection is equivalent to learning how the sparsity
structure of o↵-diagonal element in precision matrix varies with X.
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3.4.3 Parameterization of the conditional precision function
In Lemma 2, we define the conditional precision function, which can be parameter-
ized with linear or nonlinear form. Suppose we have a set of exogenous covariates X,
which can include discrete and continuous covariates. According to our assumption,
!ii(x) = !ii. With  ij(x) =  !ij(x)!ii ,  ij(.) can be functionally determined by !ij(.),
which is restricted to be equal to !ji(.) in precision matrix. If we use a linear function
to model the relationship between the partial correlations and exogenous covariates,
!ij(.) can be parameterized through X:
!ij(X) =
qX
s=1
 ijs Xs (3.2)
, where  ijs is the e↵ect of discrete or categorical variable Xs on the edge (i, j).
Although we parameterize the conditional precision function specific to our problem
in the following analysis, we discuss several instances for parameterization.
(1) The functional relationship between !ij and X is equal to that between ⇢ij and
X.
(2) The parameterization should be adapted to real background of X, because the
regularization method for covariate selection can be a↵ected by the manner of
parameterization. For example, in our case study of tumor heterogeneity problem,
a cell mean model is preferred for respectively shrinking edges in both pure tumor
and normal graphs.
(3) For categorical covariates Z, edge regression is a group-specific model. Dummy
coding of Z with interaction terms between di↵erent groups can borrow strength
for estimation.
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For each single regression for edge (i, j), the conditional precision function can be
considered as a variant of varying coe cient model (Hastie and Tibshirani, 1993). In
this work, we only discuss the estimation problem in the setting of a linear expression
for the conditional precision function. In the section of case studies, we present our
parameterization strategy for several specific problems.
3.4.4 Bayesian adaptive shrinkage
As previously discussed, the sparseness of estimated precision matrix given exogenous
covariates corresponds to the absence of edges in a subject-level graph. It has been
shown that most genomic graphs can be truly sparse. In other words, the estimated
precision matrix ⌦(X) is expected to be sparse enough, so !ij is shrunk if there is no
evidence for it to be non-zero. We adopt a Bayesian approach to combine local regu-
larization for each regression parameter with global shrinkage of the regularizing pa-
rameters across edges for each exogenous covariate (O’Hara et al., 2009). Edges with
small magnitude of elements in precision matrix after shrinkage will be threshed out.
Assuming a linear model for conditional precision function, !ij(X) =
Pq
s=1  
ij
s Xs,
we impose local shrinkage model with normal-gamma prior to shrink  ijs with weak
evidence to be non-zero towards 0. The shrinkage of  ijs can lead to the shrinkage
of  ijs xs. ⇢
ij given X with most of  ijs xs shrunk towards zero will also be shrunk
towards zero at the same time. Then we set a standardized threshold to thresh out
small ⇢ij given X to accomplish the edge selection. Normal-gamma prior benefits
us by only extreme shrinkage of “small” coe cients but weak shrinkage of “large”
coe cients (Gri n et al., 2010). The existence of closed-form posterior probability
of regularization parameters for normal-gamma prior also makes it convenient to im-
plement a Gibbs sampling method.
70
By regressing Y i over Y  i given X, we can write our model as:
Y i =
X
j 6=i
 ij(X)Y j + ✏i, i = 1, · · · , p
 ij(X) =  !
ij(X)
!ii
; ✏i ⇠ N(0, 1
!ii
)
(3.3)
Since !ij(.) is the o↵-diagonal element of precision matrix corresponding to vertex i
and vertex j, we have !ji(.) = !ij(.). Hence we can coerce these two functions to
have the same formula in the sampling scheme. Consequently, we have  ijs =  
ji
s for
every i 6= j.
We rewrite the full conditional probability of Y i as:
Y i|Y  i, { i, is }qs=1,!i,i, {Xs}qs=1 ⇠ N( 
Pp
j 6=i
Pq
s=1  
ij
s Xsy
j
!ii
,
1
!ii
) (3.4)
Normal-Gamma prior The normal-gamma prior for edge regression is given in a
hierarchical form:
 ijs ⇠ N(0, ijs ); ⇡(!ii) / 1
 ijs ⇠ Gamma( s, 1/(2 2))
(3.5)
By assuming !ii not varying with exogenous covariates, the CPF  ij(x) =  !ij(x)!ii =
 
Pq
s=1  
ij
s Xs
!ii =
Pq
s=1  
ij
s
!iiXs still satisfies a linear function. For each  
ij
s in edge
regression, a regularization parameter  ijs of normal prior is set to locally shrink each
coe cient. For di↵erent  ijs regularizing the same covariate Xs across di↵erent edges,
we have the same hyper-parameter  s,   of gamma prior to globally control them. The
scale parameter   is set to be same across all the covariates. For !ii, which controls
the variance parameter in the neighborhood selection model, we choose a vague prior
such that ⇡(!ii) / 1 as done by Gri n et al. (2010) for our following discussion. If
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!ii is given with a conjugate prior Gamma(a⇤, b⇤), the full conditional distribution
for !ii keeps the same form, so our sampling scheme can still be implemented by a
Gibbs step. A graphical representation of the hierarchical formulation corresponding
to normal-gamma prior is shown in Figure 3.1.
Figure 3.1 : A graphical representation of edge regression with normal-gamma prior.
Single arrows are probabilistic edges; double arrows are deterministic edges; squares
are observed data; circles are random variables. The total number of instances of
each variable that is enclosed in the same plate is given by the constant in the corner
of that plate. ⇢ij is the partial correlation for edge (i, j) that we want to finally get.
Sampling scheme We follow the scheme in Gri n et al. (2010) to sample  s
and   simultaneously by specifying exponential and inverse-gamma hyper priors. Ac-
cording to this hierarchy of normal-gamma prior, we implement a block Metropolis-
within-Gibbs sampling scheme to update each parameter sequentially. A summary
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of notation we use and details of our derivation can be found in Appendix B.1 and B.2.
• Update  ij for every pair (i, j), i < j
For  ij = { ijs }S of any given pair of vertex (i, j), the full conditional distribu-
tion follows a multivariate Gaussian distribution with mean
eµij =  (XTS1X + ( ij) 1) 1XTS2 (3.6)
and variance
e⌃ij = (XTS1X + ( ij) 1) 1 (3.7)
where X = (XT1 ,X
T
2 , · · · ,XTN )T is an N ⇥ q matrix with each row describing
observedX for each sample. S1 = diag(S1,1, S1,2, · · · , S1,N) is an N ⇥N -vector
and S2 = {S2,1, S2,2, · · · , S2,N}T is an N -dimensional vector. S1,n and S2,n are
given as:
S1,n =
(Y jn )
2
!ii
+
(Y in)
2
!jj
S2,n = 2Y
i
nY
j
n +Xn
T i, jY  (i,j)n
Y jn
!ii
+Xn
T j, iY  (j,i)n
Y in
!jj
(3.8)
• Update !ii, i = 1, 2, · · · , p
The full conditional distribution of !ii is:
GIG(
n
2
+ 1,
NX
n=1
(Y in)
2, diag(X i·(Y  i)T )diag(X i·(Y  i)T )T ) (3.9)
where GIG(m, a, b) is the Generalized Inverse Gaussian distribution. It has the
density
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f(x) =
(a/b)m/2
2Km(
p
ab)
x(m 1)e (ax+b/x)/2 (3.10)
• Update  ijs
 ijs for the edge (i, j) and s-covariate can be e↵ectively updated in a block since
their full conditional distributions are independent. The full conditional distri-
bution also follows a Generalized Inverse Gaussian distribution with:
GIG( s   1
2
, 1/ 2s , ( 
ij
s )
2) (3.11)
• Update hyper-parameters of the normal-gamma prior
We assigned prior ⇡( s) = exp(1) for the shape parameter  s, then the full
conditional  s is proportional to:
/ ⇡( s) 1
(2 2)
p(p 1)
2  s(  ( s))
p(p 1)
2
(
Y
i 6=j
 ijs )
 s
(3.12)
For the scale parameter  , we specify a prior
P
s  s 
2 ⇠ Ga(2,PMs)). Ms
is a hyper-parameter to approximately control the scale of  s 2 for the s-th
covariate. The calculation of Ms is discussed in our Appendix B.2 for specific
problems. We have:
  2 ⇠ Ga(2 + qp(p  1) s/2,
X
s
Ms/(2
X
s
 s) +
1
2
X
s
X
i 6=j
 ijs ) (3.13)
3.4.5 Posterior inference and thresholding
An algorithm demonstration for our MCMC sampling scheme for posterior infer-
ence is given in Algorithm 2. To carry out the edge selection after the imple-
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mentation of MCMC, we first need to calculate a posterior probability of inclu-
sion (PPI) for each edge. Given the observed data of exogenous covariates X, for
each pair of nodes (i, j), ⇢ij,ln given X = x(n) can be calculated in each iteration of
MCMC. The approach of adaptive shrinkage prior shrinks covariates towards zero
but not exact zero. So we still need to set a threshold  to indicate the inclusion
of each edge in each iteration, such that (i, j) 2 E if |⇢i,jn | >  (Hoti and Sil-
lanpa¨a¨, 2006). The marginal posterior probability of inclusion (PPI) is calculated
by Pr((i, j) 2 E|y, x(n)) =
PLT
l I(|⇢ij,ln | > )/LT , where LT is the thinned posterior
sample size after bur-in period. It is the posterior probability that the absolute ef-
fective size exceeds the given threshold. The choice of  is subjective and should be
determined based on the specific context. Too large or too small  can lead to high
false positive rate or false negative rate. In this work, we choose  = 0.1, because it
results in reasonable discovery of true positives and negatives.
Given our defined marginal posterior probability of inclusion, we select a set of
edges in a way by controlling the expected Bayesian FDR at level ↵. This rule
was first proposed for detecting di↵erentially expressed genes but we found it use-
ful in the context of edge structure discovery here by considering both statistical
and practical significance (Morris et al., 2008). If we let qi,jn denote the quantity
1  Pr((i, j) 2 E|y, x(n)), it can be considered an estimate of local FDR for selecting
edge (i, j). Following the rule of controlling global Bayesian FDR, we select the set
of edges En = {(i, j) : qi,jn <  n,↵} for each sample n. Our FDR controlling procedure
works as follow.
1. Sort {qi,jn , (i, j) 2 E} in ascending order to obtain {q(t)n , t = 1, · · · , |E|}
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2. For a given ↵, find the largest t⇤ such that (t⇤) 1Pt⇤t=1 q(t)n < ↵
3. Set  n,↵ = q
(t⇤)
n , and select edges with qi,jn <  n,↵
We control the expected Bayesian FDR at level ↵, which implies that on average
 100↵% of the edges in the set En will result in false positives. This choice of cuto↵
↵ can depend on cases because stringent ↵ leads to fewer false positive but also fewer
true positive. In our current work of simulation, we found that ↵ = 0.1 resulted a
reasonable true positive rate, false positive rate. We will also compute the average
area under the curve (AUC) of the receiver operating characteristic (ROC) curve to
examine our model performance under di↵erent thresholds of  and ↵.
Algorithm 1MCMC sampling scheme under normal-gamma prior for edge regression
1: Initialize:
{ ijs }1<i 6=j<ps2S , {!ii}pi=1, { ijs }1<i 6=j<ps2S , { s}s2S, { s}s2S
2: for iteration l = B + 1, · · · , L, (B is the burn-in period) do
3: a. update  ij,ls , !
ii,l,  ij,ls by a Gibbs step
4: b. update  s and  s by a Metropolis-Hasings step
5: for each sample n = 1, · · · , N do
6: calculate !ij,l(x(n)) from  ij,ls and x(n)
7: calculate ⇢ij,l(x(n)) from !ij,l(x) and !ii,l given X = x(n)
8: end for
9: end for
10: Output thinned posterior samples of ⇢ij(x(n))
3.5 Simulations
In this section, we include one simulation experiment to highlight the performance of
our model under the genomic background for the tumor heterogeneity problem. We
compare our proposed method with two approaches to estimating multiple graphical
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models, fused graphical lasso and group graphical lasso, in terms of edge selection
(Danaher et al., 2014). In our simulation, we have all continuous exogenous covari-
ates. This case corresponds to an important application of edge regression model to
tumor heterogeneity problem we emphasize in the section of introduction. We elab-
orate more on the problem of tumor heterogeneity in the section of simulation and
application. We also include another simulation, which is a special case of edge re-
gression when each subject-level graph is group specific. For each simulation, we run
20, 000 MCMC iterations, in which first 10, 000 iterations are discarded as a “burn-in”
period, and thin out the chain using every 10-th sample.
3.5.1 Case I: continuous exogenous covariates
In this simulation, we consider exogenous covariatesX to be continuous and simulate
data in a way from tumor sample deconvolution problem. We include 20 nodes to
represent 20 genes. We generate observed tumor expressions by log2-transforming
expressions mixed on the raw level from simulated tumor and normal components,
where log2-transformed data still satisfy a normal distribution. According to Chap-
ter 2, observed expressions from clinically derived tumor samples are assumed to be
a linear mixture of the expressions from pure normal and pure tumor components
before log2-transformation of gene expression data. It follows that,
2Yn = (1  ⇡n)2Nn + ⇡n2Tn (3.14)
where Nn ⇠ N (µN ,⌦ 1N ) and Tn ⇠ N (µT ,⌦ 1T ). ⇡n 2 [0, 1] is the measured tumor
purity for sample n.
For simplicity, we set µN = 0 and µT = 0 in our simulation. We also generate
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N 0n ⇠ N (0,⌦ 1N ) as a reference group for normal component. In the current study
of cancer pathway, expressions from normal samples, i.e. N 0, and clinically derived
tumor samples, i.e. Y , are analyzed separately. A most recent fashion construct
graphs from these tumor and normal samples by considering they are group specific.
All these attempts discover graphs from mixed expressions of Y but fail to learn the
structure for T , which represents the cancerous tumor component after removal of
normal contamination. In our following simulation, we provide two simulations with
di↵erent set-ups of precision matrix.
Simulation 1. ⌦T , where o↵-diagonal elements !
i,i+2
1 = !
i+2,i
1 uniformly sampled
from [ 0.5, 0.3] [ [0.3, 0.5] for i = 1, · · · , 18. ⌦N , where o↵-diagonal elements
!i,i+11 = !
i+1,i
1 uniformly sampled from [ 0.5, 0.3] [ [0.3, 0.5] for i = 1, · · · , 19. For
both ⌦T and ⌦N , all the diagonal elements are 1 and all the other elements are left
with zero.
Simulation 2. ⌦T , where diagonal elements !
i,i
1 = 1 for i = 1, · · · , 20 and o↵-diagonal
elements !i,i+11 = !
i+1,i
1 = 0.5 for i = 1, · · · , 19, !i,i+21 = !i+2,i1 = 0.4 for i = 1, · · · , 18.
All the other elements are left with zero. ⌦N , where we remove 30 edges randomly
from ⌦T by substituting these 30 nonzero elements with zero and randomly add 30
edges to ⌦T by substituting these 30 zero elements with values uniformly sampled
from [ 0.6, 0.4] [ [0.4, 0.6]. ⌦T is a AR(2) model. To ensure ⌦N to be positive
definite, we divide each o↵-diagonal element by 1.5 times the sum of the absolute
value of all the o↵-diagonal elements in its row. Then we average the transformed
matrix with its transpose to guarantee it is symmetric.
In our set-up of Simulation 1, ⌦T and ⌦N are truly sparse with just 18 and 19
edges. They do not have any overlapping edge and weak signal. We simulate refer-
ence normal samples of size NN 0 = 50 and mixed tumor samples of size NY = 150
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with {⇡}150n=1 generated from an arithmetic sequence from 0.01 to 0.99. In Simulation
2, we allow ⌦T and ⌦N to have 7 overlapping edges, and ⌦N has weak signals. We
simulate reference normal samples of size NN 0 = 100 and mixed tumor samples of size
NY = 200 with the same way of generating ⇡n.
We use fused and group graphical lassos that are available in R package JGL as the
comparison method by considering Y and N 0 group specific. So mixed samples are
analyzed by these competing methods to learn the structure for pure component T
and the structure for pure component N with reference normal. Then we follow the
same procedure recommended in Danaher et al. (2014) by searching over a grid of
possible values for tuning parameter  1 and  2. We then choose the combination
that minimizes the approximate AIC( 1, 2) score. In the context of this problem,
we adopt the following parameterization for our conditional precision function:
!ij(⇡) =  ij(1  ⇡) + ↵ij(⇡) (3.15)
We parameterize the relationship between precision element and ⇡, the purity of
component T , in a similar way with cell mean models. With purity of component N
being 1 ⇡, the population-level graph of pure component T and N can be given by
 ij and ↵ij straightforward because:
!ij(⇡) =
8><>:  
ij, ⇡ = 0
↵ij, ⇡ = 1
(3.16)
Hence the shrinkage over  ij and ↵ij makes shrinkage of edge strength in graph for
T and N more smooth. The hyper-parameter MN and MT is set by calculating
⌦ˆMLE respectively for samples with tumor purity below 0.5 and above 0.5. This
derivation is intuitive, since only the scale of M is of primary importance for a as a
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hyper-parameter. We implement these methods across 100 simulated data sets for
the first simulation, 77 simulated data sets for the second simulation. We evaluate the
accuracy of estimating the graph structure in terms of the true positive rate (TPR),
false positive rate (FPR) and the area under the ROC curve (AUC). For both two
graphical lasso methods and our method, we all have two threshold parameters. (
and ↵;  1 and  2). Hence, we calculate a bivariate AUC (McGu↵ey and et al, 2017)
by varying both two parameters at the same time. TPR and FPR are provided for
 = 0.1 and ↵ = 0.1. Results for those two simulations above are given in Table
3.1 and 3.2. In Simulation 1, since there is no weak signal in both normal and
tumor graphs, all those three methods can achieve high TPR and bAUC in learning
structure of normal graph. The edge regression method is able to discover fewer
false edges to give FPR lower than 0.1 no matter for normal or tumor graph. It
outperforms the other lasso methods in terms of all these three measures for the edge
selection of tumor graph, for which we do not provide any reference information.
In Simulation 2, the small magnitude of elements in precision matrix makes the
structure of normal graph more di cult to be learnt. Our method still keeps a
low FPR, even though the TPR is decreased. The edge regression method is more
powerful in learning structure of tumor graph and our bAUC is higher than the other
two methods across all these simulation settings. The corresponding bivariate ROC
curves are provided in Figure 3.2. A bivariate ROC curve describes how the average
true positive changes with average false positive through controlling two thresholds.
In those lasso methods, the fused lasso and the group lasso penalty are added to
respectively penalize di↵erences between groups and elements across all precision
matrices in addition to lasso penalty applied to the element of precision matrices
(Danaher et al., 2014). With two discrimination thresholds, even though for one
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false positive value, there could be many di↵erent corresponding true positive values.
We calculate the averaged (or maximum) false positive corresponding to each true
positive value. Hence, the ROC curve might not be monotone.
Table 3.1 : Results of edge selection for Simulation 1 in terms of TPR, FPR and
bAUC. The numbers are averaged across 100 simulated sets and the standard devia-
tions are given within the parentheses.
Method Normal Tumor Overall
Fused graphical lasso
TPR 0.993 (0.018) 0.812 (0.117) 0.902 (0.060)
FPR 0.510 (0.075) 0.355 (0.093) 0.433 (0.080)
bAUC 0.948 (0.010) 0.674 (0.060) 0.811 (0.029)
Group graphical lasso
TPR 0.993 (0.018) 0.824 (0.103) 0.908 (0.053)
FPR 0.522 (0.086) 0.366 (0.100) 0.444 (0.090)
bAUC 0.939 (0.014) 0.769 (0.051) 0.854 (0.026)
Bayesian edge regression
TPR 0.982 (0.028) 0.838 (0.095) 0.910 (0.049)
FPR 0.094 (0.027) 0.083 (0.027) 0.089 (0.019)
bAUC 0.947 (0.011) 0.916 (0.030) 0.932 (0.016)
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Table 3.2 : Results of edge selection for Simulation 2 in terms of TPR, FPR and
bAUC. The numbers are averaged across 77 simulated sets and the standard devia-
tions are given within the parentheses.
Method Normal Tumor Overall
Fused graphical lasso
TPR 0.887 (0.062) 0.983 (0.021) 0.935 (0.035)
FPR 0.532 (0.105) 0.552 (0.086) 0.542 (0.092)
bAUC 0.730 (0.039) 0.774 (0.025) 0.752 (0.019)
Group graphical lasso
TPR 0.876 (0.068) 0.984 (0.023) 0.930(0.038)
FPR 0.536 (0.103) 0.556 (0.087) 0.546 (0.091)
bAUC 0.758 (0.040) 0.819 (0.019) 0.788 (0.021)
Bayesian edge regression
TPR 0.479 (0.095) 0.957 (0.033) 0.718 (0.050)
FPR 0.047 (0.023) 0.267 (0.045) 0.157 (0.023)
bAUC 0.803 (0.037) 0.912 (0.020) 0.857 (0.019)
Figure 3.2 : Simulation of Section 3.5.1. ROC curves for structure learning of simu-
lated normal and tumor graphs in Simulation 1 and Simulation 2.
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3.5.2 Case II: categorical exogenous covariates
In this simulation, we just consider the categorical exogenous covariates. There is
a well-known multiple graphical models problem, where the estimated graphs share
some common features. We construct graphs with related dependence structures and
also add variables to each of them. We include p = 20 nodes and consider the follow-
ing three precision matrices to simulate data from three groups.
Group1. ⌦1 = ⌦T , which is the precision matrix of tumor component in Simulation
2 of Case 3.5.1.
Group2. ⌦2, where we remove 5 edges randomly from ⌦1 by substituting these 5
nonzero elements with zero and randomly add 5 edges to ⌦1 by substituting these 5
zero elements with values uniformly sampled from [ 0.6, 0.4] [ [0.4, 0.6].
Group3. ⌦3, where we randomly remove 10 edges in E1 \ E2 from ⌦2 by substi-
tuting these 10 nonzero elements with zero and randomly add 10 edges in E \ (E1 [
E2)to ⌦2 by substituting these 10 zero elements with values uniformly sampled from
[ 0.6, 0.4][ [0.4, 0.6]. E is the set of all possible edges and E1, E2 are sets of edges
corresponding to ⌦1 and ⌦2, respectively.
Then ⌦2 and ⌦3 is processed using the same procedure in Section 3.5.1 to make it
positive definite. Although this procedure is able to guarantee generated matrix to
be positive definite, it can bring weak signals to ⌦2 and ⌦3, which makes the esti-
mation even more di cult. All these three graphs have the same sparsity (37 edges)
and every pair of two graphs have overlapping edges.
Given these three matrices, we generate three groups of random samples Y(k), k =
1, 2, 3 of size N(k) = 100 from the corresponding normal distributionN (0,⌦ 1k ). With
grouped data including 300 observations, we have an exogenous covariate Z = 1, 2, 3
which is a categorical variable for each observation. We first dummy code Z using
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3 binary variables X1, X2 and X3 to correspond to each group k, i.e., Yn 2 k ,
Xk,n = 1, X k,n = 0 for observation n. Then we add the interaction terms to borrow
strength between the groups. Since we have 3 groups, the number of interaction term
is C23 + 1 = 4. Our conditional precision function !(X) can be given as follows:
!ij(X) =  ij1 X1+ 
ij
2 X2+ 
ij
3 X3+ 
ij
4 X1X2+ 
ij
5 X1X3+ 
ij
6 X2X3+ 
ij
7 X1X2X3 (3.17)
The parameterization in equation 3.17 is useful for borrowing of strength in that for
a given edge (i, j),  ij1 ,  
ij
2 and  
ij
3 indicate the unshared strength in each group,  
ij
4 ,
 ij5 and  
ij
6 indicate the shared strength just between two groups, and  
ij
7 indicate
the shared strength among all these three groups. It demonstrates the advantage of
a regression form over discrete covariates for borrowing strength. Here is a table for
the dummy coding looks like for observations in each group.
We generate 50 simulated data sets and then implement our edge regression model to
Table 3.3 : Table of dummy coding for multiple graphical models (K = 3)
group X1 X2 X3 X1X2 X1X3 X2X3 X1X2X3
k=1 1 0 0 1 1 0 1
k=2 0 1 0 0 1 1 1
k=3 0 0 1 1 0 1 1
estimate the graph structure. For the purpose of comparison, we still apply the fused
graphical lasso and joint graphical lasso following the same procedure in Section
3.5.1. For the hyper-parameter {Ms}s=1,··· ,7 in our model, we set {Ms}s=1,··· ,3 by
calculating ⌦ˆMLE for observations in each group, set {Ms}s=4,··· ,6 by calculating ⌦ˆMLE
for observations in each union of every two groups and set M7 by calculating ⌦ˆMLE
for all the observations. We still evaluate the performance of structure learning for all
the methods in terms of TPR, FPR and bAUC. In Table 3.4, we show the TPR, FPR
84
and bAUC averaged across 50 simulated data sets for the selection of edges of each
group. Figure 3.3 shows the corresponding ROC curves. TPR and FPR of Bayesian
edge regression in Table 3.4 is calculated from the results using  = 0.1 and   = 0.1.
Table 3.4 : Results of edge selection for simulated examples in terms of true positive
rate (TPR), false positive rate (FPR) and bivariate area under the curve (bAUC). The
numbers given in this table are averaged across 50 simulated sets and the standard
deviations are given within the parentheses. The last column provides the average
value across three groups.
Method Group 1 Group 2 Group 3 Overall
Fused graphical lasso
TPR 1.000 0.791 0.799 0.863
(0.000) (0.095) (0.087) (0.054)
FPR 0.504 0.322 0.335 0.387
(0.071) (0.088) (0.095) (0.079)
bAUC 0.891 0.864 0.824 0.860
(0.013) (0.020) (0.024) (0.016)
Group graphical lasso
TPR 1.000 0.775 0.782 0.852
(0.000) (0.089) (0.083) (0.051)
FPR 0.538 0.368 0.383 0.429
(0.078) (0.096) (0.108) (0.089)
bAUC 0.875 0.828 0.807 0.837
(0.013) (0.025) (0.030) (0.016)
Bayesian edge regression
TPR 1.000 0.591 0.559 0.717
(0.000) (0.097) (0.087) (0.042)
FPR 0.168 0.048 0.047 0.087
(0.033) (0.023) (0.019) (0.015)
bAUC 0.949 0.853 0.831 0.877
(0.005) (0.027) (0.038) (0.017)
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Figure 3.3 : Simulation of Section 3.5.2. ROC curves for structure learning of graphs
for simulated three groups.
Results show that both fused and group graphical lassos identify a large number
of false edges although they are able to give a high true positive rate. The Bayesian
edge regression method has very lower false positive rate but also lower true positive
rate. In the setting of multiple Gaussian graphical models, our method is able to
improve the specificity at a small cost of sensitivity. According to the measure of bi-
variate AUC, the Bayesian edge regression method outperforms both graphical lasso
methods in terms of edge selection.
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3.6 Application
3.6.1 Gene networks of prostate adenocarcinoma given tumor hetero-
geneity
We performed a case study to demonstrate how to apply our edge regression model
in a TCGA cancer data, for which we can respectively construct graphs for normal
tissues and tumor tissues to study how the regulatory network varies with the tumor
purity in the cancer samples. We downloaded prostate adenocarcinoma (PRAD) data
from TCGA data portal (Network et al., 2015b), which consist of RNA-seq gene ex-
pression data from normal blood samples and tumor tissues samples. TCGA normal
samples are provided as a control group for tumor samples. They should contain
no cancerous tissue thus have 0% tumor purity. We choose samples with consistent
proportion estimates estimated from di↵erent selected gene sets, consisting of 48 nor-
mal tissue samples and 211 tumor tissue samples through DeMixT. Those estimates
are highly consistent with estimated tumor purity from ABSOLUTE, which analyzes
somatic DNA alterations (Carter et al., 2012), on those samples (Fig. 3.4). We focus
on 87 genes in Androgen Receptor (AR) signaling pathway, which has been found to
be a critical determinant of the phenotype of prostate cancer cells (Chen et al., 2008;
Network et al., 2015b). In TCGA PRAD samples, the size of normal samples can
limit the study of the regulatory networks for the normal tissues, because a number
of covariance selection methods cannot work or obtain stable estimates when the
number of variables (i.e., p) is larger than the number of samples (i.e., n). But this
problem can be overcome by our ER method, because the large size of mixed tumor
samples, which comprise normal tissues, can borrow strength to the estimation of
network structure for the normal samples. With estimated tumor purity, we applied
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our graphical regression model on the expression data of those genes.
Figure 3.4 : The proportion estimates from DeMixT has a high concordance correla-
tion with ABSOLUTE purity estimates, which is inferred from the analysis of somatic
DNA alterations.(Carter et al., 2012)
.
We have 259 samples totally with tumor purity ranging from 0 to 1. Pure normal
samples are included as a reference group to help the learning of normal structure in
tumor samples. Denote the tumor purity with ⇡n for each sample n. We parame-
terized our conditional dependence function in the same way as the simulation and
run the MCMC sampler according to the Algorithm 2. We ran MCMC samplers for
20, 000 iterations, where the first 10, 000 is a “burn-in” period, the chain was thinned
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to every tenth iteration for inference purpose. To obtain enough sparse graphs, we
choose  = 0.15 and ↵ = 0.1. We also follow previous simulation in our simulation to
recover the normal graph, the gene regulatory network for healthy tissues, and tumor
graph, the network for cancerous tissues, and present the constructed tumor and nor-
mal graphs in Figure 3.5. We find that the tumor graph has much more connected
edges than normal graph, which suggests AR signaling pathway plays an important
role of prostate cancer growth.
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Figure 3.5 : Recovered gene regulatory network of AR signaling pathway in prostate
cancer data for cancerous tissue and normal tissue. Positive edges are colored with
green and negative edges are colored with red. Common edges of two compared graphs
are provided, where edges with consistent sign are colored with blue and di↵erent sign
with black. Upper left: tumor graph; Upper right: normal graph; Lower: Common
edges.
3.6.2 Proteomic networks in hepatocellular carcinoma
In this section, we illustrate the application of edge regression model to the inference
of real-world genomic networks, where a set of exogenous covariates plays crucial roles
to account for the subject-level diversity of samples. Besides applying edge regression
for mixed tumor samples, we also use our model to respectively construct tumor and
normal graph without edge regression. We compare all those graphs and investigate
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their common structure and di↵erential edges. We ran MCMC samplers for 10, 000
iterations of a “burn-in” period followed by 10, 000 iterations, which were thinned
to every tenth iteration for inference purpose. In posterior inference, we used our
scheme to select edge and calculate its strength by setting  = 0.1 and ↵ = 0.1.
Hepatocellular carcinoma (HCC) is a primary liver cancer that causes liver-related
mortality and has an increasing incidence in developing countries. Liver cirrhosis,
which is commonly caused by hepatitis B and hepatitis C infection, is considered as
the primary factor leading to HCC, while HCC is also the major cause of death for
patients with compensated cirrhosis. Because cirrhosis is a precursor for HCC, and
patients with cirrhosis have high risk for HCC, the study of HCC always involves the
consideration of cirrhosis (Fattovich et al., 2004; Sanyal et al., 2010). Recent studies
have exposed a number of potential molecular mechanisms that is implicated in HCC.
It was reported that inflammation, metabolic process, immune response, growth fac-
tor and activation of angiogenesis inherently are associated with the activity in liver
cancer progression and development (Dhanasekaran et al., 2016; Aravalli et al., 2008).
Cytokines are produced by cells in the liver and released into the blood. For patients
with liver disease such as hepatocellular carcinoma, the observed cytokine distribu-
tion in the blood may be a mixture of cytokines released by healthy liver cells and
released by the diseased liver cells. Once again, by estimating the “tumor purity” and
accounting for it in this context we can potentially gain power to detect di↵erences
between the cytokine profiles produced by HCC and healthy liver cells. To explore the
cytokine distribution in hepatocellular carcinoma patients, we ran the CytokineMAP
(Myriad RBM, Austin TX) on plasma samples from 767 HCC patients and 200 nor-
mal controls. This CLIA-certified platform is an immunoassay that measures values
for 305 Cytokines from inflammation, immune, metabolism, growth hormone, and
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angiogenesis pathways. We are interested in comparing the cytokine network ema-
nating from tumor with that emanating from normal liver. For this work, we focus
on the network for 10 cytokines in the metabolic pathway.
Cytokines are groups of small proteins released from cells in order to influence the
function of other cells. Liver disease such as HCC can be expected to a↵ect the cy-
tokine distribution and networks, and cytokines produced by the liver are secreted
into the bloodstream and be detected. Applying deconvolution algorithms to the
normal and HCC patients, we found that a sizable number of HCC patients have
cytokine distributions like the normal controls, while others are very di↵erent. Some
HCC patients have cytokine profiles very similar to subjects with normal liver func-
tion. Others have highly aberrant cytokine profiles. For each HCC patient sample,
we apply our newly developed computational tool DeMixT for tumor deconvolution,
which we claims to outperform previous methods with respect to estimation accuracy
in Chapter 2. From this tool, we can obtain ⇡i, a measure of heterogeneity represent-
ing proportion of the cytokine signal that appears to be from tumor. In the other
word, ⇡i measures the degree of aberration in cytokine profile relative to normal, and
is measure of aggressiveness of disease. Patients with ⇡i = 0 have cytokine profiles
like normal controls, patients with ⇡i = 1 have cytokine profiles characterizing HCC
that di↵er the most from normal, while other patients have ⇡i 2 (0, 1) that can be
interpreted as proportion of cytokine expression in the plasma emanating from tumor
versus normal liver graphs we recover in this example can be used to describe HCC
induced cytokine distribution. It has been shown that the tumor purity for HCC
patient samples (Fig. 3.6) has a distribution with heavy weights around 0 and 1.
It suggests that some HCC patients have small aberrations in cytokine, while other
have more aberrations towards tumor. This attractive behavior of tumor purity mo-
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tivates us to compare cytokine graph in patients with normal liver function versus
HCC induced function, focusing on the most highly aberrated. We ran our model to
estimate normal graph, the graph of normal cytokine distribution, and tumor graph,
the graph of cytokine distribution in HCC patients with most aggressive cancer in
our following analysis.
Figure 3.6 : Density plot of estimated tumor purity of HCC tumor samples through
DeMixT.
If we estimate the cytokine network for normals and HCCs without accounting for
this heterogeneity, the tumor network will be attenuated by patients whose cytokine
distribution is normal. Thus, we would like to estimate the normal cytokine network
and a pure HCC cytokine network that weights patient samples according to ⇡i. We
introduced our edge regression method that can be used to estimate the normal and
tumor graphs and test for di↵erential edges.
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We applied the same parameterization as in the Section 3.5.2 by setting normal-
group specific coe cient ↵ and tumor-group specific coe cient  . Normal samples
are included as a reference group for inference of structure of normal graph. We
performed the normalization by centering the mean to one and scaling the standard
deviation to one and then run our algorithm and make posterior inference. Following
Section 3.5.2, we focus on 67 cytokines that union three critical signaling pathways,
the growth hormone (GH) signaling pathway, angiogenesis signaling pathway and
metabolic signaling pathway, and recovered their normal graph and tumor graph by
analyzing 967 HCC samples with their estimated tumor purity. For purpose of com-
parison, we also performed separate inferences for all those 767 liver cancer samples
to get a tumor graph without accounting for the tumor heterogeneity, and for all
those 200 normal samples to recover a normal graph. These analyses based on our
edge regression model will provide a better understanding of how the tumor purity
a↵ect the tumorigenesis of HCC.
We used the same prior setting as in Section 3.5.2, and chose tuning parameter   
that provides acceptance rate of Metropolis step at around 20% ⇠ 30%. For con-
vergence diagnostics, we first checked the trace plots of all the parameters, and they
show good mixing of MCMC chains. In particular, we calculated all the p values
of Geweke convergence diagnostic for all the parameters. The histogram of p values
under the multiple testing (Fig. 3.7) shows that the p value is uniformly distributed,
which indicates our sampling distribution has converged as stationary. After sampling
parameters, we obtained the posterior samplers {⇢ij,lN }Ll=1 and {⇢ij,lT }Ll=1 by calculating
through  !ij,l(⇡)/p!ii,l!jj,l given ⇡ = 0 and 1. Then we ran our FDR-controlling
procedure to select edges and calculate the posterior means of partial correlations
for those selected edges. We chose  = 0.1 because it gives a reasonable sparsity in
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the resulting graphs. Heatmap plots are provided under di↵erent  for comparing
the sparsity of constructed tumor graphs, normal graphs and di↵erential edges in
Appendix B. (Fig. B.1, Fig. B.2 and Fig. B.3).
Figure 3.7 : Histogram of p values under Geweke convergence diagnostic for all the
parameters we sample from the MCMC chain.
We discover 87 new edges in the inferred networks by applying our ER model,
among which 83 edges appear in either tumor or normal graph, 2 edges appear in
both tumor and normal graphs but with opposite signs of correlation, and 2 edges
appear in both graphs with the same signs of correlation but with obvious di↵erence
in scale of partial correlation.
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We report several new edges detected through ER that have interesting di↵erences
that vary with tumor purity (Fig. 3.8). In each figure, the top half panel presents the
linear curve fitted between edge strength calculated from posterior mean and tumor
purity, with its 95% credible interval; the bottom half panel shows how the posterior
probability of inclusion vary with the tumor purity. The first two of them show that
the conditional dependency between CA-15-3 and MCP-1 and that between MIP-
1,alpha and MIP-1, beta have di↵erent signs in tumor and normal graph, which sug-
gests an opposite regulatory relationship for those cytokines. Regulation relationship
between CA-15-3/MCP-1 disappears between 0.21 ⇠ 0.63, and that between MIP-
1,alpha/MIP-1, beta disappears between 0.1 ⇠ 0.79. Some other interesting edges
we present for 6Ckine/Resistin, Adiponectin/FSH, IFN-gamma/MIP-1,beta appear
on the normal graph but not the tumor graph. We also report that those edges for
Decorin/MIP-1,beta, FABP,adipocyte/IGFBP-3, HB-EGF/Kallikrein5,
IGFBP-2/IGFBP-3, HGF receptor/VEGFR-1, IL-2/LH appear on the tumor graph
but not the normal graph. We also note that IL-2/IL-10, which although have con-
sistent signs, are reported with large-scale di↵erence in the tumor and normal graph.
We believe those regulatory relationships are noteworthy for future research.
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Figure 3.8 : Some new edges detected through ER. The linear curve with 95% cred-
ible interval between the edge strength (posterior point estimate of ⇢ij) and tumor
purity are shown in the top portion. The bottom portion describes how the posterior
probability of edge inclusion changes with tumor purity. Blue lines is the probability
cuto↵ given from global FDR controlling procedure at level ↵ = 0.1 under di↵erent
tumor purity.
The resulting graphs are presented in Figure 3.9, while we also include graphs
by just running on tumor samples without setting additional covariates in the model
(Fig. 3.10). In these figures, the size of edge is proportional to the magnitude of
estimated partial correlation between corresponding cytokines, and the size of node
describes the degree of connectedness of the corresponding cytokine.
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Hepsin is identified as a hub node with a degree of 16 in the tumor graph, while it just
has 4 connected edges in the normal graph (Table B.2). Compared with Figure 3.10
, we find that node Hepsin cannot be identified with many edges that are connected
between angiogensis pathway and metabolic pathway in the tumor graph, if tumor
purity is not given to implement edge regression. It shows that edge regression is
able to identify more strong edges. Although tumor graph that is estimated without
accounting for tumor heterogeneity shares most edges with that given by edge regres-
sion, those identified edges are di↵erent regarding sign and strength. Furthermore,
the di↵erence of normal graphs suggest that the signaling function in the normal com-
ponent of tumor samples can also be a↵ected by the tumor microenvironment, which
also implies that the study of normal tissues in tumor samples potentially di↵ers from
that of normal tissues in healthy samples in cancer research.
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Figure 3.9 : Inferred cytokine signaling pathways-the GH, Angiogenesis and Metabolic
pathway through applying ER. Positive edges are colored with green and negative
edges are colored with red. Common edges with consistent signs are colored with
blue and di↵erent signs are with black. Upper-left: tumor graph; Upper-right: normal
graph; Bottom: common graph.
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Figure 3.10 : Inferred cytokine signaling pathways-the GH, Angiogenesis and
Metabolic pathway without applying ER. Positive edges are colored with green and
negative edges are colored with red. Common edges with consistent signs are colored
with blue and di↵erent signs are with black. Upper-left: tumor graph; Upper-right:
normal graph; Bottom: common graph.
In addition to this analysis on a union of those three pathways, we also applied
our model to another two important pathways, the inflammation and immuno path-
way, to study the networks for these two separate pathways. We ran our MCMC
algorithm and implemented the posterior inference in the same way to recover their
tumor and normal graphs. All the p values of Geweke convergence diagnostic indi-
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cate good mixings of MCMC chains for sampling distributions for these two pathways
(Fig. 3.11). We summarize results given in the figures as below (Fig. 3.12, Figure
3.13, Figure 3.14 and Figure 3.15). ER detect more edges for both tumor and normal
graph in the inflammatory signaling pathway, but fewer edges for normal graph in
the immune signaling pathway. The hub genes on both tumor and normal graphs
also change between applying and without applying ER (Table B.3 and Table B.4).
MIP-1, beta is identified as a hub gene of the inflammatory pathway in both tumor
and normal graph through ER. Those findings may be noteworthy for future clinical
studies.
Figure 3.11 : Histogram of p values under Geweke convergence diagnostic for all the
parameters we sample from the MCMC chain. The left figure is for the inflammation
pathway; the right figure is for the immuno pathway.
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Figure 3.12 : Inferred inflammatory cytokine signaling pathway through applying
ER. Positive edges are colored with green and negative edges are colored with red.
Common edges with consistent signs are colored with blue and di↵erent signs are
with black. Upper-left: tumor graph; Upper-right: normal graph; Bottom: common
graph.
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Figure 3.13 : Inferred inflammatory cytokine signaling pathway without applying
ER. Positive edges are colored with green and negative edges are colored with red.
Common edges with consistent signs are colored with blue and di↵erent signs are
with black. Upper-left: tumor graph; Upper-right: normal graph; Bottom: common
graph.
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Figure 3.14 : Inferred immune cytokine signaling pathway through applying ER. Pos-
itive edges are colored with green and negative edges are colored with red. Common
edges with consistent signs are colored with blue and di↵erent signs are with black.
Upper-left: tumor graph; Upper-right: normal graph; Bottom: common graph.
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Figure 3.15 : Inferred immune cytokine signaling pathway without applying ER. Pos-
itive edges are colored with green and negative edges are colored with red. Common
edges with consistent signs are colored with blue and di↵erent signs are with black.
Upper-left: tumor graph; Upper-right: normal graph; Bottom: common graph.
3.7 Discussions
In this chapter, we introduce a novel model, Bayesian edge regression, for construc-
tion of non-static undirected graphs varying with exogenous covariates. We claim
the significance of developing a new tool to include environmental factors into reg-
ulatory networks in genomic analyses, especially for cancer research, the results of
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which can be significantly skewed. We bridge edge strength with exogenous covari-
ates through our defined conditional precision function and apply a joint regression
model for estimation. Our proposed method also explicitly guarantees the symmetry
of estimated precision matrix. The Bayesian adaptive shrinkage approach imposes
the sparsity of both precision matrix and the relationship between edges and covari-
ates. Our sampling scheme employs a Gibbs sampler, which leads to rapid mixing of
MCMC chain. Our hyper priors for normal-gamma shrinkage prior are set to allow
the borrowing of information for regularization parameters of covariate coe cient
across di↵erent edges. Our sampling procedure is also coherent and suggests simple
priors for updating hyper-parameters. We show di↵erent parameterizations of our
conditional precision function with its practicality through simulation study. We also
demonstrate that our method is able to provide a reasonable sensitivity and specificity
for edge selection. The parameterization is flexible and has been shown to be able to
borrow strength in a group-specific setting. We then apply our method for the data
of cytokine measurements from blood plasma samples, including normal samples and
tumors from hepatocellular carcinoma with tumor purity estimates.
Although in our current work, we do not include a discussion of sampling scheme
for nonlinear case, the conditional precision function is allowed to be nonlinear, and
spline-based semi-parametric methods can be employed for the parameterization. We
will extend our work to incorporate the nonlinear relationship in the future. More-
over, the precision matrix for Gaussian distribution should be positive definite. In
reality, the estimator of our method is not guaranteed to be a positive definite ma-
trix. More generally speaking, all regression-based method does not guarantee the
positive definiteness, but it does not a↵ect our primary objective for edge selection
instead of estimating a matrix. Finally, we believe our work will help in construction
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of networks from heterogeneous genomic data.
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Chapter 4
Logistic Regression with Scaling Factor
Accounting for Tumor Purity
4.1 Abstract
Diagnostic classification of patient samples is an integral part of analyzing gene ex-
pression data in cancer research. Logistic regression is a standard tool for prediction
of binary outcomes. In genome-wide association study, the number of genes far ex-
ceeds the number of observed subjects. Lasso penalized logistic regression is always
added to implement the selection of predictive genes for case-control disease in can-
cer studies. However, tumor tissues consist of a variety of non-cancerous cells, which
have been claimed to contaminate the gene expression patterns of tumors in a lot
of literature, as well as cancerous cells. Just as what we discuss about in the first
two chapters, the proportion of cancerous cells, the tumor purity, varies widely in
tumor samples. Thus, when a clinical outcome mainly associated with cancerous
cells is predicted for tumor samples, a direct application of logistic regression neglects
di↵erent contributions for di↵erent samples caused by di↵erent tumor purity and is
highly sensitive to this deviation of underlying assumptions. We propose a logistic
regression model with scaling factor that relates the tumor purity to the uncertainty
of observation for improving robustness and providing more accurate estimation. Our
model is able to quantify the uncertainty of each sample using the tumor purity for
both estimation and prediction. We present strategy for fitting our model in both
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settings of logistic regression and penalized logistic regression. We show that our
method is able to work well through a set of simulations. Finally, we believe our
method will reduce the bias introduced by tumor purity in binary classification on
genomic analyses for tumor samples.
4.2 Introduction
The more recent development of gene expression profiling technologies to measure
whole-genome mRNA abundance has contributed to the genome-wide association
study for identification of disease genes and prognostic prediction for patients (Simon,
2003). The vast amount of gene expression data can help the disease classification
in a lot of previous attempts of genomic analyses (Dettling and Bu¨hlmann, 2004). It
has been shown that patients from acute lymphoblastic leukemia (ALL) and acute
myeloid leukemia (AML) can be classified by using microarray data (Golub et al.,
1999). Gene expression profiles have also been used to predict clinical status of some
human cancer (West et al., 2001). A wide variety of methods have been proposed
for building classification models using genomic data, which include classification tree
(Dudoit et al., 2002), support vector machine (Guyon et al., 2002), relevance vector
machine (Li et al., 2002), Gaussian Process (Chu et al., 2005), partial least squares
(Nguyen and Rocke, 2002) and logistic regression. Our work considers the logistic
regression, which has become a prevalent method for binary classification by using
gene expression data (Cawley and Talbot, 2006; Liao and Chin, 2007; Sartor et al.,
2009; Wu et al., 2009; Zhu and Hastie, 2004). In high-dimensional gene expression
data, the number of predictors p always far exceeds the number of samples N , thus
lasso penalized logistic regression lends strength to feature selection by adding a L1
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penalty term. This penalty can be tuned to select a set of small number of discrim-
inatory biomarker genes for predicting case-control disease. The use of penalized
logistic regression is able to implement a prognostic prediction at the same time with
association mapping of biomarker genes.
Genome-wide association study also has important implications of understanding ge-
netic basis for cancers. It is also a primary task to select predictive biomarker genes
and classify clinical status associated with tumors in cancer research (West et al.,
2001). However, tumor samples show the cellular heterogeneity due to the intricate
microenvironment where tumor grows. The clinically derived tumor samples consist
of abundant non-cancerous cells, including a variety of stromal and immune cells.
The content of cancerous cells, which is termed as tumor purity, can vary widely
among di↵erent samples. There have been a few studies to disclose the potentially
negative e↵ects of tumor purity in clustering of cancer subtypes (Aran et al., 2015).
Tumor purity problem can introduce significant bias into genomic analyses, includ-
ing the predictive classification of tumor samples. The non-cancerous component in
tumor contaminates the expression patterns after profiling, which may under-detect
the gene expression signatures associated with the clinical outcomes for cancer prog-
nosis. Implementation of conventional classification method could yield misleading
results without taking the tumor purity into account. A number of deconvolution
methods for purifying individual gene expression profiles have appeared to aim at
this problem, including DeMixT we mention in Chapter 2. They are claimed to be
able to recover the expression patterns for cancerous component as well as estimate
tumor purity, which helps the logistic regression applied to high-dimension genomic
data (Nikooienejad et al., 2016). However, we find that our recovered expression
profiles also have systematic biases that increases with the decrease of tumor purity
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(Fig. 4.1). It makes sense because deconvolution results are artificial, thus more pure
tumor samples could have more power for recovery of cancerous signals. Therefore,
for whichever expression data we choose to do classification, raw or deconvolved, it
is important to build a classification model based on logistic regression that is able
to account for tumor purity for quantifying the power of individual observation in
regression.
Figure 4.1 : Estimated tumor-specific expression profiles from DeMixT present biases
that varies with tumor purity. It shows how the Pearson correlation (COR) and root
mean square error (RMSE) between estimated expression values and truth for each
sample change with tumor purity in a simulation study of deconvolution. Estimation
for samples with higher purity are more precise than those with lower purity.
Robust regression is designed to circumvent the limitation of conventional regres-
sion method when data are contaminated and model assumption is violated. Weighted
least squares (WLS) is a well-known technique to remedy the heteroscedasticity of ob-
served data in linear regression. Under normality WLS estimators can be transformed
to maximum weighted likelihood estimators (MWLE), which maximizes a weighted
version of log-likelihood function (Vandev and Neykov*, 1998). The weighted meth-
ods, with underlying heuristics from MWLE, have also been applied in Bayesian
regression model, which is known as power prior (Ibrahim and Chen, 2000). There
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have been several robust estimator developed in logistic regression, and a discussion is
presented to investigate the robustness of those estimators according to the contami-
nation in method (Carroll and Pederson, 1993). A method of maximum weighted has
also been proposed and discussed for logistic regression (Sˇimeckova´, 2005). We are
motivated by those weighted robustness methods and aim to assign more weight to
data with larger tumor purity when the likelihood function is maximized. However,
MWLS is unable to explain the contamination in test data for prediction after fitting
the regression model, and fails to investigate how the uncertainty a↵ects the regres-
sion, therefore wastes the provided data of tumor purity for tumor samples used for
prediction. Furthermore, the choice of a proper set of weights may heavily a↵ect the
robustness of estimation, and remains open to be discussed for the specific biological
problems (e.g. analyze read counts according to the quality of RNA samples) (Law
et al., 2014).
In this chapter, we develop a logistic regression model with an inherent scaling fac-
tor function instead of directly weighting the likelihood function. This scaling factor
helps to quantify the power of data through relating it to the tumor purity for both
estimation and prediction. We provide a preferable form of scaling factor function,
and then show our strategies for estimating scaling parameter in logistic regression
and tuning it in penalized logistic regression through cross validation. Finally, we
validate our model by in binary classification through simulation studies.
The remainder of this chapter is organized as follows. In Section 4.3, we give a formal
description of logistic regression with its latent variable interpretation. Then we flesh
out a scaling factor model with strategies for fitting parameters in logistic regression
and penalized logistic regression. We include a set of simulation studies in Section
4.4. Section 4.5 provides the concluding remarks.
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4.3 Methods
4.3.1 Logistic regression
In genomic studies of binary outcomes, the response variable Yi can be coded as
1 for cases and 0 for controls. For each observation i, we have a p dimensional
predictor vector xi = (1, xi,1, xi,2, · · · , xi,p 1)T , where xi 2 Rp is the gene expres-
sion profiles in our discussion, so p can be up to thousands or tens of thousands.
Let X = (x1,x2, · · · ,xn)T , which is an n ⇥ p matrix. Given a random vector
yn = (y1, y2, · · · , yn), where yi 2 {0, 1}, logistic regression is used to model the
posterior probabilities of the two classes through a linear expression of xi.
log
Pr(Yi = 1|Xi = x)
Pr(Yi = 0|Xi = x) = x
T
i   (4.1)
where   = ( 0,  1, · · · ,  p 1)T is a p dimensional vector of regression coe cients.
The probability Pr(Yi = 1|Xi = x) of observation i given the predictor vector xi and
coe cient vector   can be written as:
pi = Pr(Yi = 1|Xi = x) = exp(x
T
i  )
1 + exp(xTi  )
(4.2)
To fit the regression model, we estimate   through maximizing the log-likelihood
function
L( ) =
nX
i=1
{yi log pi + (1  yi) log(1  pi)} =
nX
i=1
{yixTi     log(1 + exp(xTi  ))} (4.3)
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We first introduce our scaling factor model for the logistic regression, and then we
include a sparse model into our discussion.
4.3.2 Latent variable model
The logistic regression can be interpreted through a latent variable model. Suppose
we have a latent variable Y ⇤. For each observation i, we have
Y ⇤i =  
TXi + ✏i, (4.4)
, where ✏i ⇠ Logistic(0, 1) is an additive random error variable.
A well-known result can relate the interpretation of logistic regression to a form of
ordinary linear regression (Rodr´ıguez, 2007), which claims that the response variable
Yi =
8><>: 1 if Y
⇤
i > 0,
0 otherwise.
(4.5)
The error variable ✏i can be generalized to satisfy a logistic distribution with the scale
parameter s, i.e. ✏i ⇠ Logistic(0, s). Since the logistic distribution is a scale-invariant
distribution, we can divide the righthand of the equation 4.4 with the scale param-
eter s but keep Y ⇤ on the same side of 0. That is, Y ⇤i > 0 , Y
⇤
i
s > 0, 8s > 0 ,
 0TXi + ✏0 > 0, where ✏0i =
✏i
s ⇠ Logistic(0, 1) and  0 =  s . Hence, the assumption of
generalized logistic distribution for ✏i is equivalent to dividing the product of regres-
sion coe cients and covariates by the assumed scale parameter s when ✏i is assumed
to satisfy a standard distribution.
As well known in ordinary linear regression, where Yi =  TXi + ✏i
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weighted least squares, (XTWX) 1XTWY , which weight the sum of squared resid-
uals or the log-likelihood under the normality assumption for each observation by
wi (W = diag(w1, w2, · · · , wi)), can be used when the errors ✏i are assumed under
heteroscedasticity, where ✏i ⇠ N(0,  2i ), by defining the reciprocal of error variance to
be the weights, wi =
1
 2i
. It implies that in a linear regression model, an observation
with small error variance should be given a high weight in the fitting process, because
it can give relatively more information than an observation with large error variance.
Following this idea, given a set of factors zi, i = 1, · · · , n, which reflect the relative
weight of each observation for fitting a logistic regression, we define our scaling factor
model for the latent variable in the regression as follows:
Y ⇤i =  
TXi + ✏i
✏i ⇠ Logistic(0, si)
(4.6)
where si = f(zi) and f(.) is a function to define the relative weight for observation i
through z.
It can be equivalently written as:
Y ⇤i =
 TXi
si
+ ✏0i
✏0i ⇠ Logistic(0, 1)
(4.7)
Therefore, by phrasing it back to the general logistic function form, we have
yi| , xi ⇠ Bernoulli[
exp(x
T
i  
si
)
1 + exp(
xTi  
si
)
] (4.8)
We can interpret how this model quantifies uncertainty for each sample through re-
lating to additional covariates in terms of the shape of a sigmoid function. Logistic
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regression uses a standard logistic sigmoid function to model how the success prob-
ability Pr(y = 1) is a↵ected by a set of covariates. A standard logistic function is
given by f(t) = 11+exp ( t) , where in logistic regression t = x
T . In our model, the t in
the logistic function is scaled by s, which can be interpreted as the steepness of the
curve for a more general logistic sigmoid function. Then we have f(t) = 1
1+exp (  ts )
,
where the value of s can a↵ect the shape of f(t). For a logistic regression that uses a
classifying cuto↵ Pr(y = 1) > 0.5, a smaller s can stretch this probability of success
Pr(y = 1) > 0.5 towards 1 and Pr(y = 1) < 0.5 towards 0 (Fig. 4.2). Thus, the
scaling factor does not a↵ect the binary outcome but a↵ect their “scores” (i.e. the
probability of success). Classification score for a sample with smaller s will be ad-
justed by increasing the positive score and decreasing the negative score (positive: y
= 1; negative: y = 0), while both positive and negative score will be flatten towards
0.5 if the sample has comparatively larger s than other samples. It reflects how s
controls the power for each sample in estimation of logistic regression. In prediction,
s cannot change the final binary outcome, but we can still build it into prediction by
“improving” prediction scores after we model s as a function of additional covariates
indicating the contamination. Instead of directly weighting log-likelihood using addi-
tional covariates for training the model, scaling factor model will intrinsically model
the relationship between covariates and the uncertainty in the whole data set.
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Figure 4.2 : A demonstration plot to illustrate how the scaling factor a↵ect the “score”
through the logistic sigmoid function.
4.3.3 Scaling function
As mentioned previously, the function f(.) defines the relative weights of observations
through the latent error variance, where small error variance is related to large relative
weight. In our problem, since we consider the tumor purity as our scaling factors, large
relative weights are desired for observations with larger tumor purity, which indicates
more cancerous tissues or more precise deconvolved expression data contributing to
cancer diagnosis. Assume we have a set of additional covariates Z = {z1, z2, · · · , zn}
that can be used to quantify the contamination in samples. Therefore, f(.) is expected
to be a positive non-increasing function of z. Suppose sisj =
f(zi)
f(zj)
defines a ratio of
latent error variance corresponding to a relative weight ratio between observation i
and j. We parameterize f(.) for z 2 (0, 1] as follows:
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f(z) = az
0 < a  1
(4.9)
Exponential has several properties that meet our demand to define latent error vari-
ance through it.
• It is positive for z 2 R
• It is a decreasing function for a 2 (0, 1)
• It is degenerated to be equal for all observations when a = 1, so weights all the
observations equally
• The log-ratio log( f(zi)f(zj)) = log(a)⇥ (zi  zj) is linear and the magnitude of a will
control the log di↵erence
• It is equivalent to a general exponential function. Given a general exponential
function f(z) = c⇥ ad⇤z, then c⇥ad⇤zi
c⇥ad⇤zj =
ad
zi
adzj
= a
0zi
a0zj
We define a as the scaling parameter to calculate a set of scaling factors from z for
each sample. In the following sections, we discuss the choice of a for both logistic
regression and penalized logistic regression.
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4.3.4 An optimization procedure for logistic regression
With our well-parameterized scaling function, we formulate the full model as follows:
yi| , a, b, xi, zi ⇠ Bernoulli[ exp(
xTi  
azi )
1 + exp(
xTi  
azi )
]
0 < a  1
(4.10)
Although our work mainly aims at penalized logistic regression with scaling function,
we first include the estimation for logistic regression with scaling function but without
penalty term into discussion. For a that has very small magnitude, it is possible for
⌘i
azi , where ⌘i = x
T
i  , to have an intolerable large magnitude for all i. This scaling
problem can disconverge the fitting of parameters in logistic regression. We provide
two di↵erent strategies to bypass it for logistic regression and penalized logistic re-
gression problem. We generalize the scaling function to f(z) = az + b, where b   0 is
a shift term to a↵ect the magnitude of f(z). It can slightly a↵ect the ratio of weights
between di↵erent observations but not a↵ect the other properties mentioned above.
With parameters a and b in the scaling function, we have our log-likelihood function
as:
L( , a, b) =
nX
i=1
{yi x
T
i  
azi + b
  log(1 + exp( x
T
i  
azi + b
))} (4.11)
This objective function is not strictly convex after adding a and b, but we can still de-
sign an optimization procedure to find a local optimum for  , a, b and finally compare
this solution to  ˆ0.  ˆ0 represent the MLE estimates of regression coe cients when
we fix a = 1 and b = 0, which is also the original solution without introducing the
weights. When we have a best solution of the original logistic regression problem, we
only need to see if our current solution improves the estimation performance. We de-
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sign an optimization procedure via coordinate descent. We keep the Newton-Raphson
step for updating   (Dobson and Barnett, 2008; Venables and Ripley, 2013; R Core
Team, 2016), but just insert a step to update a and b through a golden section search
with parabolic interpolation. Our optimization procedure is given as follows:
1. Initialize  (0), a(0) and b(0)
2. Update  , a, b through coordinate descent
In iteration t
• Update x(t)s,i = xis(t)i , where s
(t)
i = (a
(t 1))zi + b(t 1)
• Update  (t) = (X(t)s TWX(t)s ) 1X(t)s TWz,
where z = Xs (t 1)+W 1(y p(x(t))s,i ;  (t 1))),W = diag{p(x(t))s,i ;  (t 1))(1 
p(x(t))s,i ;  
(t 1))}, p(x(t))s,i ;  (t 1)) = exp( 
(t 1)T x(t))s,i
1+exp( (t 1)T x(t))s,i
)
• Search 0 < a(t)  1 and b(t)   0 such that  L(a, b;  (t)) is minimized
• Until convergence condition is satisfied
Notice in the Newton-Raphson step, we can use a Newton-downhill method to guar-
antee the objective function  L( , a, b) to be strictly non-increasing in this step. As
long as the algorithm is convergent, we keep the estimated a, b and   for the purpose
of prediction.
4.3.5 Penalized logistic regression with L1 penalty
To implement a feature selection for logistic regression, we subtract a L1 penalty term
from the log-likelihood function. In lasso penalized logistic regression, we maximize
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the objective function w.r.t:
1
N
nX
i=1
{yixTi     log(1 + exp(xTi  ))}   | | (4.12)
, where   is the tuning parameter to control the amount of shrinkage.
Including our scaling function to the penalized logistic regression, we have our objec-
tive function to be:
1
N
nX
i=1
{yix
T
i  
azi
  log(1 + exp(x
T
i  
azi
))}   | | (4.13)
Because a can a↵ect the magnitude of  , L1 norm of which is bounded by a pre-
specified parameters t = t( ), we cannot directly estimate a by maximizing the ob-
jective function given the tuning parameter  . Actually when we estimate a, in each
iterative step si and   tend to become smaller, which finally fails to converge. The
value of scaling parameter may be data dependent. There has been one approach to
selecting weights for the WLME through cross-validation (Wang et al., 2005). Similar
to its analogy, we also propose an implementation of cross validation to select a as a
tuning parameter as well as  . To bypass the potential convergence problem caused
by abnormal scale of x
T
i  
si
for the logistic function, we divide each scaling factor with
a normalization constant aa0 . Then we have:
1
N
nX
i=1
{yix
T
i  
azi a0
  log(1 + exp( x
T
i  
azi a0
))}   | | (4.14)
The parameter a0 does not a↵ect the relative weights
si
sj
between two observations,
because a0 will be cancelled o↵ in
azi a0
azj a0
. In addition, the scaling function f(z) = az a0
still satisfy all these properties we claim above. The choice of a0 is subjective, and we
recommend to use a0 = median(z) if z is more uniformly distributed. By setting this
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in the equation, we have no more than 50% observations with latent error variances
no less than 1 and no more than 50% observations with latent error variances no
larger than 1. A grid search can then be implemented to select   and a at the
same time following the minimum validation error rule or one standard error rule. In
fitting the regression model, we first obtain x0i by dividing the predictor vector xi =
(1, xi,1, xi,2, · · · , xi,p 1)T by azj a0 for each i (Note: we need to include the intercept
term to be scaled by azj a0). The method of cyclical coordinate descent (Friedman
et al., 2010) and proximal gradient method (Rockafellar, 2015) are commonly used to
find the regularized path for logistic regression. With x0i as the predictor vector, in
our example we apply the proximal gradient method for regularization. The selection
procedure of a amounts to a sequence of nested loops given in Algorithm 2. This
cross validation scheme performs a grid search for a and  .
Algorithm 2 Cross validation scheme for selecting a with   in penalized logistic
regression
H
1: for increment a 2 (0, 1) do
2: a. compute a sequence of  a at which the largest value makes all coe cients
shrink to zero given si = azi a0 .
3: b. cross validation
4: for increment  a do
5: run the proximal descent method on the penalized logistic problem by
scaling the rows of predictor matrix by (s1, s2, · · · , sn)
6: compute and record validation error CV ( , a) and standard error SE( , a)
over all folds of validation set
7: end for
8: end for
9: choose ( , a) s.t
1.  ˆ, aˆ minimize CV ( , a) or
2. one standard error rule: the most sparse model with CV ( , a)  CV ( ˆ, aˆ)+
SE( ˆ, aˆ)
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4.4 Simulations
In this section, we include three simulation studies for logistic regression respectively
with and without an L1 penalty. We compare the performance of our method with
the logistic regression model without scaling factor function. Our simulations are de-
signed to correspond to the tumor heterogeneity problem we emphasize in our work,
where the datasets are simulated following the model assumption from the previous
tumor deconvolution works.
4.4.1 Simulation 1: logistic regression
In this simulation, we include 200 samples, where 150 samples are used as the training
data for model fitting and 50 samples are used as the test data for reporting the pre-
diction errors. The element of the true design matrix X is generated from a normal
distribution, i.e. xi,p ⇠ N(µx, 1), where µx ⇠ N(7, 1.5). We generate an observed
design matrix in a way following Chapter 2, which assumes the observed expression
profiles from clinically derived tumor samples to be a linear mixture of profiles con-
tributed by pure normal and pure tumor components before log2-transformation of
gene expression data. We generate ni,p ⇠ N(µn, 0.5), where µn ⇠ N(7, 1.5). We
log2-transform a weighted sum of 2xi,p and 2ni,p with weights ⇡i and 1  ⇡i to obtain
a observed x0i,p, which simulates the contamination of xi,p by ni,p. The equation un-
derlying simulation is given as below:
2X
0
i = (1  ⇡i)2Ni + ⇡i2Xi (4.15)
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, where Ni ⇠ N (µN ,⌦ 1N ) and Xi ⇠ N (µX ,⌦ 1X ). ⇡i 2 [0, 1] is the purity of X for
the observation i.
We assign ⇡ = {⇡1, ⇡2, · · · , ⇡n} with an arithmetic sequence from 0.05 to 0.99 re-
spectively in the training data and test data. We set the intercept  0 to be 1. The
following combinations of   are used to generate non-zero coe cient.
(1)  = {1, 2, 3}; (2)  = {2, 3, 4}; (3)  = {1, 2, 3, 4, 5}; (4)  = {2, 3, 4, 5, 6}.
We first standardize the columns in X to satisfy a standard normal distribution.
Then we generate yi ⇠ Bernoulli( exp(x
T
i  + 0)
1+exp(xTi  + 0)
). We normalize the observed data X 0
in the training and test data. We run 200 simulations, where each non-zero coe cient
setting above is simulated for 50 times.
We compute the average area under the curve (AUC) of the receiver operating charac-
teristic (ROC) curve and the mean squared error of prediction (MSE). MSE is defined
by:
MSE =
||yˆ   y||22
n
=
Pn
i (yˆi   yi)2
n
(4.16)
Table 4.1 summarizes the performance of our logistic regression model with scaling
function (LGSF) on mixed data and deconvolved data compared with the original
logistic regression model (LG). Results show that LGSF can improve the prediction
performance for both mixed data and deconvolved data in terms of AUC and MSE.
The logistic regression using deconvolved data is also preferred to using mixed data.
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Table 4.1 : Results of binary classification of test set in Simulation 1 in terms of MSE
and AUC with standard errors (SE) in the bracket over 200 simulated datasets.
Mixed data Mixed data deconvolved data deconvolved data
(LG) (LGSF) (LG) (LGSF)
AUC 0.808 (0.007) 0.827 (0.007) 0.810(0.007) 0.838 (0.006)
MSE 0.1770 (0.0015) 0.1707 (0.0014) 0.1760 (0.0015) 0.1655 (0.0015)
4.4.2 Simulation 2: penalized logistic regression
In this simulation, we have a similar setting for generating observed and hidden pre-
dictor matrix in the logistic regression. We include p = 1000 covariates and have p0
covariates with non-zero coe cients, where p0 2 {3, 5}. The four combinations of   in
the first simulation are kept in this simulation, and the mixing manner of Ni and Xi
for generating X 0i is same. The only di↵erence is that we generate some mixed sam-
ples with purity ⇡ = 1, which is considered as the pure tumor samples to stabilize the
estimation. After simulating the observed predictor matrix, we also apply our tumor
deconvolution tool DeMixT to resolve Xi for each sample. We notate the recovered
predictor matrix through deconvolution as Xˆi. Next, we implement L1 penalized
logistic regression on Xi, X 0i and Xˆi, and apply our scaling factor model on X
0
i and
Xˆi. We assign 200 samples in training data, and 100 samples in test data, and finally
compare their prediction performance in the test set. The results are summarized in
Table 4.2 in terms of AUC and MSE for both mixed data and deconvolved data using
LG and LGSF.
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Table 4.2 : Results of binary classification of test set in Simulation 2 in terms of MSE
and AUC with standard errors (SE) in the bracket over 200 simulated datasets.
Mixed data Mixed data deconvolved data deconvolved data
(LG) (LGSF) (LG) (LGSF)
AUC 0.780 (0.007) 0.789 (0.007) 0.795 (0.007) 0.806 (0.007)
MSE 0.206 (0.001) 0.205 (0.001) 0.204 (0.001) 0.198 (0.001)
The large number of features to be estimated in the penalized logistic regression
makes prediction di cult to be improved for a contaminated data set. But our model
can still improve AUC and reduce MSE for both mixed data and deconvolved data.
By using deconvolved data, it can also improve the prediction performance. Finally,
we can realize an improvement of 0.026 in AUC through applying our model on the
deconvolved data.
4.5 Discussion
In this chapter, we demonstrate that the traditional logistic regression model is not
robust to model cancer-associated clinical status without accounting for cellular het-
erogeneity of tumors. We construct a scaling factor model in logistic regression to
incorporate tumor purity for quantifying the uncertainty caused by non-cancerous
cells’ contamination or the measurement error from deconvolution tools. We also
present the strategies to estimate or tune up scaling parameter for logistic regression
and penalized logistic regression. Results on the data simulated from the tumor con-
volution model clearly demonstrate that our proposed model can improve prediction
performance compared with traditional logistic regression model. Although our scal-
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ing factor model is proposed for logistic regression, it can still be extended to any
sigmoid function based model. Furthermore, we propose our model for the problem of
tumor cellular heterogeneity, but our model is more general to be applied to problems
of classifying contaminated data. For tuning scaling parameters in cross validation,
we currently implement a search on a fixed grid of evenly spaced value from 0 to 1.
Further work is needed to provide narrower search range for improving e ciency, as
well as study the theoretical properties of our model and other modifications of the
scaling factor function.
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Chapter 5
Conclusions and Perspectives
5.1 Conclusions
The recent advancement of statistical methods proposed for genomic studies, such as
classification and correlation, provide deeper insights into the association among the
activities of genes under di↵erent biological conditions. Cancer researchers benefit
from using statistical technique to help them better detect the expression patterns of
genes. However, the cellular heterogeneity of tumors has posed a great challenge to
the application of conventional genomic methods that analyze gene expression pat-
terns for a homogeneous population. There have been several studies that disclose
their significant influences on caner biology by confounding the biological interpreta-
tion of genomic analysis results for tumors. One research has shown that acquired
resistance to VEGF inhibitor bevacizumab is associated with these gene expression
changes that occur predominantly in stromal but not tumor cells, which suggests that
understanding stromal signaling pathway is also critical for cancer biomarker study
(Cascone et al., 2011). The other study has questioned the potential joint role of
JAK3 and CSF1R in a caner-driving pathway after finding that their tandem ex-
pressions in bladder carcinoma di↵ered seriously with the tumor purity. They also
uncovered falsity on the relative expressions for two important proteins in cancer
immunotherapy, CTLA-4 and CD86, between the results taking tumor purity into
account and those that do not (Aran et al., 2015). Following those demands for more
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powerful statistical methodologies in cancer biology, we put forward a series of topics
on statistical modeling for cellular heterogeneity problems. We set out to develop
an in silico deconvolution method for expression data, which outperforms previous
methods in estimation accuracy and account for more variability in normal cell popu-
lations. We test our deconvolution method from biologically simulated data and real
data, and discover some interesting biological finding through our method. Next, we
are motivated to design a new statistical model to serve for the construction of gene
regulatory networks of tumor samples. We develop a novel class of undirected graph-
ical models, the edge regression model, which can utilize the tumor purity we obtain
from the deconvolution as an indicator of the degree of genomic aberration from
normals to investigate the dynamic structure change of networks in heterogeneous
tumors. Our edge regression method is firstly proposed for the cellular heterogeneity
problems of studying molecular pathways, but it is a more generalized model, which
overcomes the deficiencies of current conditional covariance selection methods. Di-
agnostic prediction is another field of interest for cancer study. When a prediction
model is built to find enriched biological groups for a case-control factor associated
with a cancer disease, we want to have a more robust binary classification method
for heterogeneous tumors, of which the expression pattern, even though for decon-
volved data, is a↵ected by how cancerous tissues contribute. In our dissertation, we
develop an integrated pipeline of statistical modeling methods, from deconvolution,
to correlation and classification, to aid immensely resolving the cellular heterogeneity
problems in cancer studies.
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5.2 Perspectives
This thesis develops a couple of statistical modeling approaches to the cellular het-
erogeneity problems. We aim to promote the development of statistical methods for
incorporating tumor heterogeneity, and emphasize that extensions based on our work
would be of great interest for future research. We suggest several important directions
that can be extended in future work.
First, the identifiability of tumor deconvolution problem is not trivial. As discussed in
Chapter 2, tumor deconvolution models, with whichever assumed underlying distri-
bution for deconvolved signals, cannot guarantee the identifiability for estimation of
component proportions. For existing deconvolution models, it is di cult to obtain a
global optimization solution. Actually the best local optimums we are able to obtain
do not only depend on the initialization, but also on the selection of genes for de-
convolution. Di↵erent subset of genes selected for deconvolution can lead to di↵erent
proportion estimates. Due to those properties, gene selection plays a crucial role in
deconvolution, even more important than modeling and optimization design in some
case. All the current literature on deconvolution lacks consideration and discussion
of gene selection. Our work discusses about this issue and provides several empirical
strategies, but a systematic study of gene selection for deconvolution with strictly
theoretical discussion is expected for future research.
Second, it is desirable to include a non-linear parameterization along with its infer-
ence scheme in our edge regression model. The relationship between edge strength
and exogenous covariates in our proposed edge regression model can be allowed to
be linear or non-linear. We provide the sampling scheme for the linear relationship
in this work. In the future work, spline-based semi-parametric representations can
be used to adapt the conditional precision function. A generalized mixed model for
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spline functions can help to develop a sampling scheme with similar logics for infer-
ence of linear relationship.
Third, it would be of great value to integrate tumor deconvolution with graphical
models. On one side, as demonstrated in Chapter 3, tumor deconvolution techniques
all require an individually independence assumption for gene expression. This is a very
strong assumption, and it is actually contrary to the co-regulation and co-expression
fact of genes. Some neighboring genes tend to be correlated on expression in tumor
samples. Current strategy for deconvolution lacks the technique to include correla-
tion analysis into inference. On the other side, current edge regression model utilizes
the tumor purity, which is estimated from deconvolution, to infer subject-level and
population-level graph, but the bias caused by the inference of deconvolution, would
be introduced to the construction of networks. This secondary bias is hard to be esti-
mated. Therefore, an integrated model to combine deconvolution of tumor expression
pattern and construction of subject-level gene networks will contribute significantly
to both of those two aspects, and even could potentially help to solve the gene selec-
tion problem.
All the three directions following my thesis work will prominently pave a road for
the future work of statistical modeling and provide an aid to develop more precise
and powerful tool for cellular heterogeneity problems. In sum, we resolve the cellular
heterogeneity problems by applying statistical approaches including deconvolution,
Gaussian graphical models and logistic regression to help the genomic analyses of
tumor samples. Cancer biology is still making faster and faster progress to expose
more and more interesting findings. With such advances, I hope my thesis would
motivate more in-depth studies and provide new insights into related research topics
in cancer studies.
131
132
Appendix A
Cell type-specific Deconvolution of Heterogeneous
Tumor Samples using Expression Data
A.1 Proof of Local Optimality for ICM Algorithm
In these iterative steps of ICM, the complete likelihood is updated by searching con-
ditional modes. It never decreases at any iteration and eventual convergence to the
local maximum is guaranteed.
We organize the descriptive proof of local optimality as follows. In the t-th itera-
tion, we search the maximum {⇡(t)1 , ⇡(t)2 }i of f({⇡1, ⇡2}i; {yig}Gg=1, {µ(t 1)T ,  (t 1)T }Gg=1)
for each sample i = 1, · · · , S by using a golden search and successive parabolic inter-
polation.
Our complete likelihood function can be expressed as a product:
L({⇡1, ⇡2}Si , {µT ,  T}Gg=1) =
SY
i=1
f({⇡1, ⇡2}i, {yig}Gg=1, {µT ,  T}Gg=1). (A.1)
Then, this sample-wise maximum leads to
L({⇡(t)1 , ⇡(t)2 }Si , {µ(t 1)T ,  (t 1)T }Gg=1)   L({⇡(t 1)1 , ⇡(t 1)2 }Si , {µ(t 1)T ,  (t 1)T }Gg=1). (A.2)
Similarly, we search the maximum {µ(t)T ,  (t)T }g of f({µT ,  T}g; {yig}Si=1, {⇡(t)1 , ⇡(t)2 }Si=1)
for each gene i = 1, · · · , G. Our complete likelihood function can be alternatively
expressed as a product:
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L({⇡1, ⇡2}Si , {µT ,  T}Gg=1) =
GY
g=1
L({µT ,  T}g, {yig}Si=1, {⇡1, ⇡2}Si=1). (A.3)
Then, this genome-wise maximum leads to
L({⇡(t)1 , ⇡(t)2 }Si , {µ(t)T ,  (t)T }Gg=1)   L({⇡(t)1 , ⇡(t)2 }Si , {µ(t 1)T ,  (t 1)T }Gg=1). (A.4)
Therefore we have a new inequality by combining the two aforementioned inequalities:
L({⇡(t)1 , ⇡(t)2 }Si , {µ(t)T ,  (t)T }Gg=1)   L({⇡(t 1)1 , ⇡(t 1)2 }Si , {µ(t 1)T ,  (t 1)T }Gg=1). (A.5)
Thus, assuming we start with a guess for vector {µ(0)Tg ,  (0)Tg}g for each g = 1, · · · , G
for a local maximum of our complete likelihood L, and considering the sequence
{{⇡(0)1 , ⇡(0)2 }Si , {µ(0)T ,  (0)T }Gg=1}, {{⇡(1)1 , ⇡(1)2 }Si , {µ(1)T ,  (1)T }Gg=1} ,{{⇡(2)1 , ⇡(2)2 }Si , {µ(2)T ,  (2)T }Gg=1}, · · · ,
we have
L({⇡(0)1 , ⇡(0)2 }Si , {µ(0)T ,  (0)T }Gg=1)  L({⇡(1)1 , ⇡(1)2 }Si , {µ(1)T ,  (1)T }Gg=1)
 L({⇡(2)1 , ⇡(2)2 }Si , {µ(2)T ,  (2)T }Gg=1)  · · ·
(A.6)
The sequence {{⇡(t)1 , ⇡(t)2 }Si , {µ(t)T ,  (t)T }Gg=1} should converge to the desired local opti-
mum.
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A.2 Supplemental Tables
Table A.1 : Summary of datasets GEO19830 with the mixture proportions (%) of rat
liver, brain and lung, three of which are isolated as pure type tissue.
Mixture Number of Technical Replicate Tissue Type Liver Brain Lung
1 3 Pure 100 0 0
2 3 Pure 0 100 0
3 3 Pure 0 0 100
4 3 Mixed 5 25 70
5 3 Mixed 70 5 25
6 3 Mixed 25 70 5
7 3 Mixed 70 25 5
8 3 Mixed 45 45 10
9 3 Mixed 55 20 25
10 3 Mixed 50 30 20
11 3 Mixed 55 30 15
12 3 Mixed 50 40 10
13 3 Mixed 60 35 5
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Table A.2 : Summary of datasets in RNA-seq mixed cell lines experiment with
the mixture proportions (%) of lung adenocarcinoma in humans (H1092), cancer-
associated fibroblasts (CAFs) and tumor infiltrating lymphocytes (TIL), three of
which are isolated as pure type tissue.
Mixture Number of Technical Replicate Tissue Type H1092 CAF TIL
1 2 Pure 100 0 0
2 2 Pure 100 0 0
3 2 Pure 100 0 0
4 2 Pure 0 100 0
5 2 Pure 0 100 0
6 2 Pure 0 100 0
7 2 Pure 0 0 100
8 2 Pure 0 0 100
9 2 Pure 0 0 100
10 2 Mixed 45.6 50.8 3.6
11 2 Mixed 45.6 50.8 3.6
12 2 Mixed 45.6 50.8 3.6
13 2 Mixed 61.9 35.6 2.5
14 2 Mixed 61.9 35.6 2.5
15 2 Mixed 61.9 35.6 2.5
16 2 Mixed 29.6 68 2.4
17 2 Mixed 29.6 68 2.4
18 2 Mixed 29.6 68 2.4
19 2 Mixed 43.2 49.7 7.1
20 2 Mixed 43.2 49.7 7.1
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21 2 Mixed 43.2 49.7 7.1
22 2 Mixed 63 36.2 0.9
23 2 Mixed 63 36.2 0.9
24 2 Mixed 63 36.2 0.9
26 2 Mixed 30 69.1 0.8
27 2 Mixed 30 69.1 0.8
28 2 Mixed 30 69.1 0.8
29 2 Mixed 81.9 17.7 0.4
30 2 Mixed 81.9 17.7 0.4
31 2 Mixed 81.9 17.7 0.4
32 2 Mixed 93.6 6 0.4
33 2 Mixed 93.6 6 0.4
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A.3 Supplemental Figures
Liver: 5%, Brain 25% Liver: 70%, Brain 5%
Liver: 25%, Brain: 70% Liver: 70% , Brain: 25%
Liver: 45%, Brain: 45% Liver: 55%, Brain: 20%
Liver: 50% , Brain: 30% Liver: 55%, Brain: 30%
Liver: 50%, Brain: 40% Liver: 60%, Brain: 35%
Figure A.1 : Scatter plots of Yig   Tig   ⇡2,i(N¯2,g   Tig) versus N¯1,g   Tig and
Yig   Tig   ⇡1,i(N¯1,g   Tig) versus N¯2,g   Tig for raw measured data at 10 di↵erent mixture
ratios. Red dash line denotes the fitted regression coe cient for all probes by least squares; blue
dash line denotes the truth purity; blue dots denote the probes we remove; green dots denote the
remaining probes, from which the expression level of at least two of three tissues measure above
27 for deconvolution. If the linearity holds, the fitted line by regression on green dots should be
approximate the line with slope equal to the true proportion.)
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Appendix B
Bayesian Edge Regression for Undirected
Graphical Model Accounting for Biological
Heterogeneity
B.1 Summary of Notation
The context of edge regression enables the use of index set for exogenous covariates,
which makes it complicated in notation. We summarize the notation of random vec-
tors and their matrix form.
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Table B.1 : Summary of notation
Symbol Description
s index of exogenous covariate
i, j index of vertex
n index of sample
q number of exogenous covariates
p number of vertices
N sample size
 ijs edge regression coe cient of s-th covariate for edge (i, j)
 ij = ( ij1 ,  
ij
2 , · · · ,  ijq )T q-dimensional random vector of  ijs
  = ( 1,2, 1,3, · · · , p 1,p) q ⇥ p(p 1)2 -matrix of  ij
Xs,n the s-th covariate of sample n
Xn = (X1,n, X2,n, · · · , Xq,n)T q-dimensional random vector of exogenous covariates
for sample n
X = (XT1 ,X
T
2 , · · · ,XTN )T N ⇥ q-matrix of exogenous covariates
Y in random variable of vertex i in graph for sample n
Yn = (Y 1n , Y
2
n , · · · , Y pn )T p-dimensional random vector for sample n
Y = (Y T1 ,Y
T
2 , · · · ,Y TN )T N ⇥ p-matrix of observed data
 ijs scale parameter of normal prior for the s-th covariate
of edge (i, j)
 ij = diag( ij1 , 
ij
2 , · · · , ijq ) q ⇥ q-matrix of scale parameter of posterior probability
for edge (i, j)
eµij , e⌃ij parameter of normal prior for  ij
S1,n element of calculation for eµij , e⌃ij
S1,n element of calculation for eµij , e⌃ij
S1 = diag(S1,1, S1,2, · · · , S1,N) N ⇥N -matrix of S1,n
S2 = {S2,1, S2,2, · · · , S2,N}T N -dimensional vector of S2,n
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B.2 Details and Derivation of MCMC Sampling
In equation 3.3 we condition the precision matrix ⌦ on a set of exogenous covariates X.
Instead of modeling  ij(x), we model the conditional precision function on !ij(x) under the
regression setting. Since the precision matrix is symmetric, we have !ji(.) = !ij(.). Hence,
we can coerce these two functions to have the same form in the sampling scheme. When
we regress !ij(.) on X in a linear setting :
!ij(x) =
qX
s=1
 ijs Xs (B.1)
We have  ijs =  
ji
s for every i 6= j. Then we have a complete likelihood given by equa-
tion 3.4. In the context of using normal-gamma shrinkage prior, the posterior distribution
of all parameters in our model can be updated through a Gibbs sampling scheme. We
will also follow the normal-gamma prior paper (Gri n et al., 2010) to talk about updating
hyper-parameters for normal-gamma prior through a Metropolis-Hasting step in our model.
Update  ij for every pair (i, j), i < j For  ij = { ijs }S of any given pair of vertex
(i, j), we derive the full conditional by
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f( ij |.) / f(Y i|Y  i, { i, (i,j)s }qs=1, { i,js }qs=1,!i,i, {Xs,n}q,Ns=1,n=1)
⇥ f(Y j |Y  j , { j, (i,j)s }qs=1, { i,js }qs=1,!j,j , {Xs,n}q,Ns=1,n=1)⇥ f( i,j | i,j)
/ exp{ 1
2
NX
n=1
[
(Y in +
Pp
k 6=i
Pq
s=1  
ik
s Xs,nY
k
n
!ii )
2
(!ii) 1
+
(Y jn +
Pp
k 6=j
Pq
s=1  
jk
s Xs,nY kn
!jj )
2
(!jj) 1
]}
⇥ f( i,j | i,j)
/ exp{ 1
2
NX
n=1
[2Y in
pX
k 6=i
qX
s=1
 iks Xs,nY
k
n +
(
Pp
k 6=i
Pq
s=1  
ik
s Xs,nY
k
n )
2
!ii
+ 2Y jn
pX
k 6=j
qX
s=1
 jks Xs,nY
k
n +
(
Pp
k 6=j
Pq
s=1  
jk
s Xs,nY kn )
2
!jj
]}⇥ f( i,j | i,j)
/ exp{ 1
2
NX
n=1
[4Y inY
j
n
qX
s=1
 ijs Xs,n
+
2
P
k 6=(i,j),s  
ik
s Xs,nY
k
n
Pq
s=1  
ij
s Xs,nY
j
n + (
Pq
s=1  
ij
s Xs,nY
j
n )2
!ii
+
2
P
k 6=(i,j),s  
jk
s Xs,nY kn
Pq
s=1  
ij
s Xs,nY in + (
Pq
s=1  
ij
s Xs,nY in)
2
!jj
]}⇥ f( i,j | i,j)
/ f( i,j | i,j)⇥ exp{ 1
2
NX
n=1
[(
qX
s=1
 ijs Xs,n)
2(
(Y jn )2
!ii
+
(Y in)
2
!jj
)
+ 2
qX
s=1
 ijs Xs,n(2Y
i
nY
j
n +
P
k 6=(i,j),s  
ik
s Xs,nY
k
n Y
j
n
!ii
+
P
k 6=(i,j),s  
jk
s Xs,nY kn Y
i
n
!jj
)]}
(B.2)
In the equation above, we simplify it by denoting:
S1,n =
(Y jn )2
!ii
+
(Y in)
2
!jj
(B.3)
and
S2,n = 2Y
i
nY
j
n +
X
k 6=(i,j),s
 iks Xs,nY
k
n
Y jn
!ii
+
X
k 6=(i,j),s
 jks Xs,nY
k
n
Y in
!jj (B.4)
For simplification of notation we have:
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X
k 6=(i,j),s
 iks Xs,nY
k
n =X
T
n 
i, jY  (i,j)n
X
k 6=(i,j),s
 jks Xs,nY
k
n =X
T
n 
j, iY  (j,i)n .
(B.5)
, where  i, j corresponds to the columns that include i but not j in the superscript in
 , and Y  (i,j)n corresponds to the remaining elements in the vector Yn after removing i-th
and j-th element. This way, we rewrite:
S2,n = 2Y
i
nY
j
n +Xn
T i, jY  (i,j)n
Y jn
!ii
+Xn
T j, iY  (j,i)n
Y in
!jj
(B.6)
We also have:
qX
s=1
 ijs Xs,n = ( 
ij)TXn
(
qX
s=1
 ijs Xs,n)
2 = ( ij)TXnXn
T ij
(B.7)
Hence, we have:
B.2 = f( i,j | i,j)⇥ exp{ 1
2
NX
n=1
[( ij)TXnXn
T ijS1,n + 2( 
ij)TXnS2,n]}
/ exp 1
2
[( ij)T ( ij) 1 ij +
NX
n=1
(( ij)TXnS1,nXn
T ij + 2( ij)TXnS2,n)]
= exp 1
2
[( ij)T ( ij) 1 ij + (( ij)T
NX
n=1
XnS1,nXn
T ij + 2( ij)TXnS2,n)]
= exp 1
2
[(( ij)T (
NX
n=1
XnS1,nXn
T + ( ij) 1) ij + 2( ij)T
NX
n=1
XnS2,n)]
(B.8)
According to equation B.8, we have  ij |. ⇠ N(eµij , e⌃ij),where
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eµij =  ( NX
n=1
XnS1,nXn
T + ( ij) 1) 1
NX
n=1
XnS2,n
e⌃ij = ( NX
n=1
XnS1,nXn
T + ( ij) 1) 1
(B.9)
For further simplification, we formulate S1 and S2 in a matrix form according to Section
B.1. The calculation of element-wise Xn
T i, jY  (i,j)n is complicated in S2. We calculate
this component vector through matrix algebra, where
{XnT i, jY  (i,j)n }Nn=1 = diag(X i, j(Y  (i,j))T ) (B.10)
Then we can express (11) as:
eµij =  (XTS1X + ( ij) 1) 1XTS2
e⌃ij = (XTS1X + ( ij) 1) 1 (B.11)
Update !ii, i = 1, 2, · · · , p By setting f(!ii) / 1, we derive the full conditional by:
f(!ii|.) / f(Y i|X,Y  i, { i, (i,j)s }qs=1, { i,js }qs=1,!i,i, Xs,n)⇥ f(!i,i)
/ (!ii)n2 exp{ 1
2
NX
n=1
[
(Y in +
Pp
k 6=i
Pq
s=1  
ik
s Xs,nY
k
n
!ii )
2
(!ii) 1
]}
/ (!ii)n2 exp{ 1
2
NX
n=1
[(Y in)
2!ii +
(
Pp
k 6=i
Pq
s=1  
ik
s Xs,nY
k
n )
2
!ii
]}
/ (!ii)n2 exp{ 1
2
[!ii
NX
n=1
(Y in)
2 +
NX
n=1
Xn
T i·Y  in (Y  in )T ( i·)TXn
!ii
]}
/ (!ii)n2 exp{ 1
2
[!ii
NX
n=1
(Y in)
2 +
diag(X i·(Y  i)T )diag(X i·(Y  i)T )T
!ii
]}
(B.12)
Hence, !ii|. ⇠ GIG(n2+1,
PN
n=1(Y
i
n)
2, diag(X i·(Y  i)T )diag(X i·(Y  i)T )T ) , where GIG
is the Generalized Inverse Gaussian distribution.
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Update  ijs We sample  
ij
s according to
f( ijs |.) / f( ijs | ijs )⇥ f( ij | s,  ) (B.13)
That is equally,  ijs ⇠ GIG( s   12 , 1/ 2, ( ijs )2)
Update  s and   Instead of using cross validation technique to select   and   in normal-
gamma prior, we choose to sample these parameters by specifying hyper-priors. We update
 s and   through a Metropolis-Hasting sampling method.
If we use ⇡( s) to denote the prior of  s, we can have the full conditional of  s as
f( s|·) / ⇡( s) 1
(2 2)
p(p 1)
2  s(  ( s))
p(p 1)
2
(
Y
i 6=j
 ijs )
 s
(B.14)
, where we set ⇡( s) ⇠ exp(1).
We have multiplicative random walk updates on  s through  ⇤s = exp( 2 sz) s, where z
satisfies a standard normal.  2 s is a tuning parameter for random walk and it is chosen
so that the acceptance rate is around 20% to 30%. Then the acceptance function is given by:
min
⇢
1,
 ⇤s
 s
⇡( ⇤s)
⇡( s)
(2 2)
p(p 1)
2  
⇤
s (  ( ⇤s))
p(p 1)
2
(2 2)
p(p 1)
2  s(  ( s))
p(p 1)
2
(
Y
i 6=j
 ijs )
 ⇤s  s
 
(B.15)
For the scale parameter  , we follow the suggested setting in normal-gamma prior paper
(Gri n et al., 2010), with
P
s  s 
2 ⇠ Ga(2,PMs)). Ms is a hyper-parameter to approxi-
mately control the scale of  s 2 for the s-th covariate, so we provide a heuristic solution to
it by calculating the mean square error between zero and o↵-diagonal elements in maximum
likelihood estimator (MLE) of ⌃ corresponding to each s. Ms =
P
1ijp(⌃ˆ
 1
s,ij)
2
p(p 1)/2 , where
⌃ˆ 1s is the inverse of the estimated Gaussian covariance matrix through MLE for samples
considering the e↵ect represented by the s-th covariate. When ⌃ˆs is singular, we can use
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the estimated precision matrix ⌦ˆs through a regularization method, e.g. graphical lasso
(Friedman et al., 2008), instead of ⌃ˆ 1s . The derivation of Ms is discussed case by case in
the section of simulation and case study.
Hence we have,   2 ⇠ Ga(2 + qp(p  1) s/2,
P
sMs/(2
P
s  s) +
1
2
P
s
P
i 6=j  
ij
s ).
B.3 Supplementary Tables
Table B.2 : Table of edge connectedness for the unions of the GH, Angiogenesis and
Metabolic pathway in tumor graph, normal graph and common edges under  = 0.1
(sorted by number of shared edges).
Symbol Tumor Normal Common
IGFBP6 10 7 5
IL-1 beta 10 6 5
IGFBP-3 13 5 4
MIP-1 alpha 5 4 4
EGF 6 3 3
IGFBP4 11 3 3
IGFBP5 10 4 3
IL-6 6 4 3
ITAC 11 4 3
MIP-1 beta 7 6 3
SCF 7 6 3
VEGFR-2 12 5 3
ANG-1 7 2 2
Endoglin 9 5 2
FABP, adipocyte 7 3 2
Hepsin 16 4 2
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IGFBP-2 7 6 2
IL-10 3 2 2
MMP-9, total 5 2 2
PDGF-BB 5 2 2
PECAM-1 9 3 2
PPP 3 2 2
Resistin 8 4 2
SDF-1 4 4 2
TNF-alpha 4 4 2
uPAR 10 4 2
VEGF 7 4 2
ACE 3 2 1
CA-15-3 6 1 1
CEACAM1 2 4 1
Decorin 10 2 1
FSH 2 5 1
G-CSF 1 2 1
GLP-1 total 10 3 1
HER-2 8 3 1
IFN-gamma 5 3 1
IL-1 alpha 5 4 1
IL-2 5 1 1
IL-8 8 3 1
Insulin 1 4 1
Kallikrein 5 2 1 1
KLK-7 2 1 1
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Leptin 4 3 1
LH 3 1 1
MCP-1 6 2 1
MIF 5 1 1
MMP-3 4 2 1
MSLN 8 3 1
PLGF 8 3 1
TN-C 8 1 1
TNF-beta 4 4 1
Table B.3 : Table of edge connectedness for the Inflammation pathway in tumor
graph, normal graph and common edges under  = 0.1 (sorted by number of shared
edges).
Symbol Tumor Normal Common
MIP-1 beta 11 11 6
VCAM-1 11 7 6
MMP-3 9 6 5
BDNF 9 7 4
Factor VII 5 5 4
GM-CSF 9 9 4
IL-1 beta 10 7 4
IL-12p40 9 5 4
IL-3 7 8 4
MIP-1 alpha 8 5 4
TNF-beta 6 11 4
AAT 7 6 3
B2M 7 4 3
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Fibrinogen 5 5 3
IL-1 alpha 13 3 3
IL-10 12 3 3
IL-1ra 10 8 3
IL-23 3 5 3
IL-6 5 8 3
TNF-alpha 6 5 3
IFN-gamma 7 3 2
IL-2 6 4 2
IL-7 8 9 2
IL-8 7 4 2
MMP-9 6 3 2
TIMP-1 10 4 2
TNFR2 3 3 2
VEGF 11 3 2
vWF 7 5 2
A2Macro 3 3 1
CRP 8 1 1
Eotaxin-1 4 4 1
Haptoglobin 3 4 1
IL-15 2 2 1
RANTES 9 2 1
SCF 7 3 1
VDBP 4 3 1
149
Table B.4 : Table of edge connectedness for the Immune pathway in tumor graph,
normal graph and common edges under  = 0.1 (sorted by number of shared edges).
Symbol Tumor Normal Common
Thrombospondin-1 5 5 3
IL-16 4 2 2
IL-22 6 2 2
IP-10 6 3 2
MCP-2 7 5 2
MMP-9, total 5 4 2
MPIF-1 7 2 2
MPO 6 3 2
ANG-2 11 2 1
APRIL 9 2 1
AXL 6 3 1
CD40-L 2 3 1
DKK-1 2 2 1
Eotaxin-3 4 1 1
IL-6r 9 1 1
ITAC 8 2 1
MCP-4 5 2 1
MIF 4 3 1
MMP-1 3 2 1
TARC 5 1 1
TRAIL-R3 6 2 1
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B.4 Supplementary Figures
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Figure B.1 : Heatmaps represent edge strength and 1 - PPI under di↵erent  for
normal graph. The white color indicates no connected edge. Left panel is for posterior
mean calculated for partial correlation; right panel is for 1- Posterior Probability of
Edge inclusion. On the left panel, blue indicates negative point estimates and red
indicates positive point estimates (deeper color for larger absolute value). On the
right panel, the degree of blue hue indicates the scale of local false discovery rate
(deeper blue for smaller value) for each edge.
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Figure B.2 : Heatmaps represent edge strength and 1 - PPI under di↵erent  for
tumor graph. The white color indicates no connected edge. Left panel is for posterior
mean calculated for partial correlation; right panel is for 1- Posterior Probability of
Edge inclusion. On the left panel, blue indicates negative point estimates and red
indicates positive point estimates (deeper color for larger absolute value). On the
right panel, the degree of blue hue indicates the scale of local false discovery rate
(deeper blue for smaller value) for each edge.
154
155
Figure B.3 : Heatmaps represent edge strength and 1 - PPI under di↵erent  for
di↵erential edges between tumor and normal graph. The white color indicates no
connected edge. Left panel is for posterior mean calculated for partial correlation;
right panel is for 1- Posterior Probability of Edge inclusion. On the left panel, blue
indicates negative point estimates and red indicates positive point estimates (deeper
color for larger absolute value). On the right panel, the degree of blue hue indicates
the scale of local false discovery rate (deeper blue for smaller value) for each edge.
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